CN112955448B - 芳环或芳杂环类化合物及其制备方法和医药用途 - Google Patents
芳环或芳杂环类化合物及其制备方法和医药用途 Download PDFInfo
- Publication number
- CN112955448B CN112955448B CN202080006066.5A CN202080006066A CN112955448B CN 112955448 B CN112955448 B CN 112955448B CN 202080006066 A CN202080006066 A CN 202080006066A CN 112955448 B CN112955448 B CN 112955448B
- Authority
- CN
- China
- Prior art keywords
- cyclopropyl
- azabicyclo
- compound
- preparation
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title abstract description 94
- 125000003118 aryl group Chemical group 0.000 title abstract description 37
- 125000006615 aromatic heterocyclic group Chemical group 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 113
- 102100038495 Bile acid receptor Human genes 0.000 claims abstract description 50
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims abstract description 50
- 230000000694 effects Effects 0.000 claims abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 18
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 10
- 206010008635 Cholestasis Diseases 0.000 claims abstract description 7
- 230000007870 cholestasis Effects 0.000 claims abstract description 7
- 231100000359 cholestasis Toxicity 0.000 claims abstract description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 6
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 4
- 208000008589 Obesity Diseases 0.000 claims abstract description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 4
- 208000035475 disorder Diseases 0.000 claims abstract description 4
- 235000020824 obesity Nutrition 0.000 claims abstract description 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims abstract description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 25
- 210000004185 liver Anatomy 0.000 claims description 14
- 238000009825 accumulation Methods 0.000 claims description 12
- 206010016654 Fibrosis Diseases 0.000 claims description 11
- 230000001684 chronic effect Effects 0.000 claims description 10
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 9
- 230000004761 fibrosis Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 6
- 230000002440 hepatic effect Effects 0.000 claims description 6
- 230000003211 malignant effect Effects 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 230000003463 hyperproliferative effect Effects 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 230000007882 cirrhosis Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000001024 intrahepatic cholestasis Diseases 0.000 claims description 4
- 230000007872 intrahepatic cholestasis Effects 0.000 claims description 4
- 230000000414 obstructive effect Effects 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 3
- 208000007788 Acute Liver Failure Diseases 0.000 claims description 2
- 206010000804 Acute hepatic failure Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010048832 Colon adenoma Diseases 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 206010019663 Hepatic failure Diseases 0.000 claims description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 2
- 206010019799 Hepatitis viral Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 231100000836 acute liver failure Toxicity 0.000 claims description 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 230000006020 chronic inflammation Effects 0.000 claims description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 208000037765 diseases and disorders Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 208000009866 extrahepatic cholestasis Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 231100000835 liver failure Toxicity 0.000 claims description 2
- 208000007903 liver failure Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000015768 polyposis Diseases 0.000 claims description 2
- 238000002271 resection Methods 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000001862 viral hepatitis Diseases 0.000 claims description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 abstract description 11
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- -1 triglyceride Chemical class 0.000 description 152
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 86
- 125000000217 alkyl group Chemical group 0.000 description 59
- 238000006243 chemical reaction Methods 0.000 description 50
- 125000000753 cycloalkyl group Chemical group 0.000 description 46
- 125000000623 heterocyclic group Chemical group 0.000 description 46
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 39
- 238000005481 NMR spectroscopy Methods 0.000 description 38
- 238000004949 mass spectrometry Methods 0.000 description 36
- 125000001072 heteroaryl group Chemical group 0.000 description 34
- 239000000203 mixture Substances 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 229910052736 halogen Inorganic materials 0.000 description 30
- 150000002367 halogens Chemical class 0.000 description 30
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 30
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 26
- 125000003545 alkoxy group Chemical group 0.000 description 25
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 25
- 239000000243 solution Substances 0.000 description 23
- 238000000034 method Methods 0.000 description 22
- 239000005711 Benzoic acid Substances 0.000 description 21
- 235000010233 benzoic acid Nutrition 0.000 description 21
- 229940079593 drug Drugs 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- REIDAMBAPLIATC-UHFFFAOYSA-M 4-methoxycarbonylbenzoate Chemical compound COC(=O)C1=CC=C(C([O-])=O)C=C1 REIDAMBAPLIATC-UHFFFAOYSA-M 0.000 description 20
- 239000003613 bile acid Substances 0.000 description 20
- 239000000651 prodrug Substances 0.000 description 20
- 229940002612 prodrug Drugs 0.000 description 20
- 239000007787 solid Substances 0.000 description 18
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 239000003480 eluent Substances 0.000 description 13
- 125000006413 ring segment Chemical group 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 125000003342 alkenyl group Chemical group 0.000 description 12
- 125000000304 alkynyl group Chemical group 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 125000002619 bicyclic group Chemical group 0.000 description 11
- 125000003367 polycyclic group Chemical group 0.000 description 11
- JBDOSUUXMYMWQH-UHFFFAOYSA-N 1-naphthyl isothiocyanate Chemical compound C1=CC=C2C(N=C=S)=CC=CC2=C1 JBDOSUUXMYMWQH-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 125000004093 cyano group Chemical group *C#N 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 230000035508 accumulation Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- YNVOMSDITJMNET-UHFFFAOYSA-N thiophene-3-carboxylic acid Chemical compound OC(=O)C=1C=CSC=1 YNVOMSDITJMNET-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 125000003282 alkyl amino group Chemical group 0.000 description 8
- 125000004414 alkyl thio group Chemical group 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 125000000000 cycloalkoxy group Chemical group 0.000 description 8
- 125000005366 cycloalkylthio group Chemical group 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 125000004438 haloalkoxy group Chemical group 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- KKZMIDYKRKGJHG-UHFFFAOYSA-N methyl 4-cyanobenzoate Chemical compound COC(=O)C1=CC=C(C#N)C=C1 KKZMIDYKRKGJHG-UHFFFAOYSA-N 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 125000004043 oxo group Chemical group O=* 0.000 description 7
- 230000001603 reducing effect Effects 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical group CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000007942 carboxylates Chemical class 0.000 description 6
- 239000012295 chemical reaction liquid Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 6
- 229960005132 cisapride Drugs 0.000 description 6
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 6
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical group [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 6
- KWVXDZLVCISXIB-UHFFFAOYSA-N 4-bromo-3-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1Br KWVXDZLVCISXIB-UHFFFAOYSA-N 0.000 description 5
- 108091006146 Channels Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000001270 agonistic effect Effects 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 238000007363 ring formation reaction Methods 0.000 description 5
- 125000000335 thiazolyl group Chemical group 0.000 description 5
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 4
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 4
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102100023172 Nuclear receptor subfamily 0 group B member 2 Human genes 0.000 description 4
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- XEFCWBLINXJUIV-UHFFFAOYSA-N acetic acid;iodobenzene Chemical group CC(O)=O.CC(O)=O.IC1=CC=CC=C1 XEFCWBLINXJUIV-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 108010003814 member 2 group B nuclear receptor subfamily 0 Proteins 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- 239000004530 micro-emulsion Substances 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 125000003003 spiro group Chemical group 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- CONKQHOYYHTQSI-UHFFFAOYSA-N 2-(4-bromo-3-methylphenyl)-1,3,4-oxadiazole Chemical compound C1=C(Br)C(C)=CC(C=2OC=NN=2)=C1 CONKQHOYYHTQSI-UHFFFAOYSA-N 0.000 description 3
- BFJALHSTCHFUMF-UHFFFAOYSA-N 4-bromo-3-methylbenzohydrazide Chemical compound CC1=CC(C(=O)NN)=CC=C1Br BFJALHSTCHFUMF-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012445 acidic reagent Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003722 extracellular fluid Anatomy 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- FKUAJCIRULEXLN-UHFFFAOYSA-N methyl 4-(1,3,4-oxadiazol-2-yl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=NN=CO1 FKUAJCIRULEXLN-UHFFFAOYSA-N 0.000 description 3
- PLZZPPHAMDJOSR-UHFFFAOYSA-N nonanenitrile Chemical compound CCCCCCCCC#N PLZZPPHAMDJOSR-UHFFFAOYSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229940081066 picolinic acid Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000004262 preparative liquid chromatography Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 3
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 239000011592 zinc chloride Substances 0.000 description 3
- 235000005074 zinc chloride Nutrition 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- XRXCBKITDLPTEF-UHFFFAOYSA-N 2-fluoro-4-methoxycarbonylbenzoic acid Chemical compound COC(=O)C1=CC=C(C(O)=O)C(F)=C1 XRXCBKITDLPTEF-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- IHWMWEIAAARWJH-UHFFFAOYSA-N 3-chloro-4-methoxycarbonylbenzoic acid Chemical compound COC(=O)C1=CC=C(C(O)=O)C=C1Cl IHWMWEIAAARWJH-UHFFFAOYSA-N 0.000 description 2
- BHCZVQVKEQQOAN-UHFFFAOYSA-N 3-fluoro-4-methoxycarbonylbenzoic acid Chemical compound COC(=O)C1=CC=C(C(O)=O)C=C1F BHCZVQVKEQQOAN-UHFFFAOYSA-N 0.000 description 2
- WMZNGTSLFSJHMZ-UHFFFAOYSA-N 3-methoxycarbonylbenzoic acid Chemical compound COC(=O)C1=CC=CC(C(O)=O)=C1 WMZNGTSLFSJHMZ-UHFFFAOYSA-N 0.000 description 2
- HJZFPRVFLBBAMU-UHFFFAOYSA-N 4-bromothiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC(Br)=CS1 HJZFPRVFLBBAMU-UHFFFAOYSA-N 0.000 description 2
- ZQKSVHOYMATPAD-UHFFFAOYSA-N 4-methoxycarbonyl-2-methylbenzoic acid Chemical compound COC(=O)C1=CC=C(C(O)=O)C(C)=C1 ZQKSVHOYMATPAD-UHFFFAOYSA-N 0.000 description 2
- YCNXGPMGMAKDPM-UHFFFAOYSA-N 5-bromothiophene-3-carboxylic acid Chemical compound OC(=O)C1=CSC(Br)=C1 YCNXGPMGMAKDPM-UHFFFAOYSA-N 0.000 description 2
- NTCKZTBRFXTYBD-UHFFFAOYSA-N 5-methoxycarbonylpyridine-2-carboxylic acid Chemical compound COC(=O)C1=CC=C(C(O)=O)N=C1 NTCKZTBRFXTYBD-UHFFFAOYSA-N 0.000 description 2
- HYHZGBOWRWIEGW-UHFFFAOYSA-N 5-methoxycarbonylthiophene-2-carboxylic acid Chemical compound COC(=O)C1=CC=C(C(O)=O)S1 HYHZGBOWRWIEGW-UHFFFAOYSA-N 0.000 description 2
- VWIOMFMPIVMLIR-UHFFFAOYSA-N 6-methoxycarbonylpyridine-2-carboxylic acid Chemical compound COC(=O)C1=CC=CC(C(O)=O)=N1 VWIOMFMPIVMLIR-UHFFFAOYSA-N 0.000 description 2
- QRSXLMSDECGEOU-UHFFFAOYSA-N 6-methoxycarbonylpyridine-3-carboxylic acid Chemical compound COC(=O)C1=CC=C(C(O)=O)C=N1 QRSXLMSDECGEOU-UHFFFAOYSA-N 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 108090000472 Phosphoenolpyruvate carboxykinase (ATP) Proteins 0.000 description 2
- 102100034792 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical class Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005347 halocycloalkyl group Chemical group 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000002977 intracellular fluid Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- IGHWNCLZGNNKBN-UHFFFAOYSA-N methyl 4-[(e)-n'-hydroxycarbamimidoyl]benzoate Chemical compound COC(=O)C1=CC=C(C(\N)=N/O)C=C1 IGHWNCLZGNNKBN-UHFFFAOYSA-N 0.000 description 2
- RULRGDSQDQHZOK-UHFFFAOYSA-N methyl 4-azidobenzoate Chemical compound COC(=O)C1=CC=C(N=[N+]=[N-])C=C1 RULRGDSQDQHZOK-UHFFFAOYSA-N 0.000 description 2
- 108091088477 miR-29a stem-loop Proteins 0.000 description 2
- 108091029716 miR-29a-1 stem-loop Proteins 0.000 description 2
- 108091092089 miR-29a-2 stem-loop Proteins 0.000 description 2
- 108091066559 miR-29a-3 stem-loop Proteins 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 description 2
- 229960001601 obeticholic acid Drugs 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical group [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- CRDAMVZIKSXKFV-YFVJMOTDSA-N (2-trans,6-trans)-farnesol Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO CRDAMVZIKSXKFV-YFVJMOTDSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- MGTUVUVRFJVHAL-UHFFFAOYSA-N 2,8-dibenzyl-6-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-3-ol Chemical compound Oc1c(Cc2ccccc2)nc2c(Cc3ccccc3)nc(cn12)-c1ccc(O)cc1 MGTUVUVRFJVHAL-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- MAIDVTUHEDEKMF-UHFFFAOYSA-N 3-methoxy-4-methoxycarbonylbenzoic acid Chemical compound COC(=O)C1=CC=C(C(O)=O)C=C1OC MAIDVTUHEDEKMF-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- PNZIYSWKRBYITO-UHFFFAOYSA-N 4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole Chemical compound ClC1=CC=CC(Cl)=C1C1=NOC(C2CC2)=C1CBr PNZIYSWKRBYITO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 101710134389 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2 Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000004410 Cholesterol 7-alpha-monooxygenases Human genes 0.000 description 1
- 108090000943 Cholesterol 7-alpha-monooxygenases Proteins 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102100038637 Cytochrome P450 7A1 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102100025353 G-protein coupled bile acid receptor 1 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000957672 Homo sapiens Cytochrome P450 7A1 Proteins 0.000 description 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 1
- 101000857733 Homo sapiens G-protein coupled bile acid receptor 1 Proteins 0.000 description 1
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- 101000666934 Homo sapiens Very low-density lipoprotein receptor Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000001479 Member 11 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010093662 Member 11 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100390675 Mus musculus Fgf15 gene Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 108091006611 SLC10A1 Proteins 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 101150043341 Socs3 gene Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102100021988 Sodium/bile acid cotransporter Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 1
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000058015 Suppressor of Cytokine Signaling 3 Human genes 0.000 description 1
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 1
- 102100036236 Synaptonemal complex protein 2 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102100039066 Very low-density lipoprotein receptor Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940125890 compound Ia Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000001706 diarylethene group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 150000003620 farnesol derivatives Chemical class 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940042040 innovative drug Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- GLZBUNHGODEJPT-UHFFFAOYSA-N methyl 2-chloro-4-cyanobenzoate Chemical compound COC(=O)C1=CC=C(C#N)C=C1Cl GLZBUNHGODEJPT-UHFFFAOYSA-N 0.000 description 1
- XPBHWSMZTSSEJE-UHFFFAOYSA-N methyl 3-cyanobenzoate Chemical compound COC(=O)C1=CC=CC(C#N)=C1 XPBHWSMZTSSEJE-UHFFFAOYSA-N 0.000 description 1
- PDQNYPAJSAVURS-UHFFFAOYSA-N methyl 4-cyano-2-methylbenzoate Chemical compound COC(=O)C1=CC=C(C#N)C=C1C PDQNYPAJSAVURS-UHFFFAOYSA-N 0.000 description 1
- LIXWSMOADOOTOR-UHFFFAOYSA-N methyl 4-cyano-3-methylbenzoate Chemical compound COC(=O)C1=CC=C(C#N)C(C)=C1 LIXWSMOADOOTOR-UHFFFAOYSA-N 0.000 description 1
- KLGYHLXZILYUOL-UHFFFAOYSA-N methyl 5-cyanothiophene-2-carboxylate Chemical compound COC(=O)C1=CC=C(C#N)S1 KLGYHLXZILYUOL-UHFFFAOYSA-N 0.000 description 1
- RWTWEJPTYZWMEY-UHFFFAOYSA-N methyl 6-cyanopyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(C#N)=N1 RWTWEJPTYZWMEY-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- VQSRKMNBWMHJKY-YTEVENLXSA-N n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]23[C@@H](CN(C2)C=2N=CC(F)=CN=2)CSC(N)=N3)=C1 VQSRKMNBWMHJKY-YTEVENLXSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 102000004164 orphan nuclear receptors Human genes 0.000 description 1
- 108090000629 orphan nuclear receptors Proteins 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004141 reverse cholesterol transport Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及芳环或芳杂环类化合物及其制备方法和医药用途。特别地,本发明涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物,及其作为法尼醇衍生物X受体(Farnesoid X receptor,FXR)激动剂的用途,该化合物及含有该化合物的药物组合物可以用于治疗和/或预防与FXR活性相关的疾病,例如胆汁郁积病症、糖尿病及其并发症、非酒精性脂肪肝(NAFLD)、非酒精性脂肪肝炎(NASH)、肥胖或代谢综合征(血脂异常、糖尿病和体重指数异常高的合并病症)、心血管疾病等。其中通式(I)中的各取代基的定义与说明书中的定义相同。
Description
技术领域
本发明属于医药技术领域,具体涉及一种芳环或芳杂环类化合物、其制备方法及含有其的药物组合物,以及其用于调节法尼醇衍生物X受体(Farnesoid X receptor,FXR)活性,进而用于治疗和/或预防与FXR活性相关的疾病的用途。
背景技术
法尼醇衍生物X受体(FXR)作为一种胆汁酸激活的核受体,可直接或通过孤儿核受体小异二聚体伴侣(SHP)调控多种代谢相关基因的表达。FXR于1995年被发现,其命名源于该受体可以被超生理水平的法尼醇激活。近年研究发现,胆汁酸(Bile Acids,BAs)是FXR最主要的生理配体(Drug Discovery Today,2012,17,988)。
异常水平的胆汁酸与肝部炎症和纤维化有关,相比甘油三酯,胆汁酸的蓄积是非酒精性脂肪肝的更重要致病因素。FXR的激活可通过降低肝部胆汁酸的合成和摄取,并提高胆汁酸外排,达到降低肝内胆汁酸蓄积净效应;FXR可上调SHP,SHP可抑制胆汁酸合成重要酶CYP7A1的表达,进而抑制胆汁酸合成(Pharmacol.Ther.2010,126,228-243);此外,FXR可诱导FGF15/19激活FGFR4,进而启动JNK通路,以抑制CYP7A1的表达;FXR通过上调BSEP和MRP2,抑制NTCP降低肝细胞内胆汁酸水平,刺激胆汁酸在肝细胞小管膜分泌,抑制从门静脉的胆汁酸再摄取;FXR可通过OSTα/β调控胆汁酸转运,促进胆汁酸外排至循环系统,通过肾脏消除。
FXR可改善胰岛素抵抗,FXR基因敲除小鼠表现出了糖代谢清除的受损,表明小鼠存在外周胰岛素抵抗。FXR激活对胰岛素抵抗的改善作用可能与以下机制有关:FXR可降低外周组织(如肌细胞)脂质的蓄积,进而降低脂质相关毒性,特别是针对饮食导致的肥胖患者(Acta.Pharmacol.Sin.2015,36,44-50);小肠FXR的激活可促进FGF19释放入门静脉,FGF19具有一定的胰岛素增敏作用,另有报道FGF19具有降低体重作用,FGF19转基因小鼠表现了较强抵抗饮食诱导肥胖作用;FXR可降低糖异生和肝糖输出,胆酸喂养小鼠可抑制糖异生相关酶,如PEPCK、G6P等基因的表达,但对于SHP敲除小鼠无作用;FXR激动剂可降低小鼠PEPCK和G6P,同时降低肝糖的输出。
FXR可通过多种途径降低甘油三酯和脂肪酸的产生,并促进其代谢。FXR可通过抑制SREBP1c的表达,抑制甘油三酯和脂肪酸的合成及分泌,促进VLDLR的表达,提升VLDL和乳糜微粒的清除,抑制APOC和MTP的表达,抑制VLDL的组装,诱导PPARα,促进脂肪酸的β氧化,诱导脂蛋白脂肪酶,进而增强脂蛋白和游离脂肪酸的代谢作用。FXR通过正调控SRBI、CEH、SCP2等促进HDL的摄取和胆固醇的逆转运,还可通过抑制PCSK9的表达和活性,增强LDLR和LDL的清除,达到降低胆固醇的作用(Curr.Opin.Lipidol.2016,27,295-301)。
FXR可通过下调多种炎症相关基因的表达抑制炎症,FXR与炎症反应密切相关,FXR基因敲除小鼠具有较高的促炎症和促纤维细胞因子水平,包括TNFα、ICAM-1、α-SMA、TIMP-1、TGFβ等。FXR对炎症和纤维化的抑制可能与以下机制有关:FXR激活的主要炎症抑制机制是拮抗NFκB信号通路;FXR激活可以改善胆道阻塞、肠道菌群过度生长、粘膜损伤、肠道细菌移位等;FXR可诱导SOCS3的抑制因子,进而抑制STAT3信号通路;FXR的激活可提升MicroRNAmir29a,MicroRNA mir29a可调节多个胞外基质蛋白的表达。此外,另有研究表明,FXR可促进肝组织再生,且抑制干细胞肿瘤的发生。因此,FXR激动剂可用于脂质特别是甘油三酯蓄积,及甘油三酯蓄积导致的慢性脂肪和纤维变性引起的疾病和病症,例如非酒精性脂肪肝(NAFLD)或非酒精性脂肪肝炎(NASH)的预防和治疗(Adv.Ther.2016,33,291-319;DrugDiscov.Today,2012,17,988-97)。
目前,FXR激动剂已成为全球创新药物研发的热门之一。其中,甾体类FXR激动剂奥贝胆酸已成功获批用于原发性胆汁性肝硬化(PBC),并在治疗NASH的临床研究(FlINT研究)表现出较好疗效,进一步FXR激动剂用于PBC和NASH治疗的合理性。但该药物作为甾体药物选择性较差,特别是对TGR5也有一定作用,容易导致严重瘙痒和高脂血症等副作用。此外,奥贝胆酸存在严重的肝肠循环,导致药物在体内存在较高蓄积,已引发安全性风险。因此,选择性更高和药代性质更优的非甾体FXR激动剂更加受到关注(Lancet,2015,385,956-65;N.Engl.J.Med.2016,375,631-643)。
非甾体FXR激动剂研究较早的是GW-4604,该化合物具有较强的体外活性,但药代性质不佳,且由于二芳基乙烯结构具有安全性风险;目前,研发进展最快、最受关注的是PX-104,该药物具有较高的FXR激动活性和药代性质,在临床前药效学模型中表现出显著降低肝脂肪蓄积和损伤的疗效,现已进入针对NASH的临床II期研究(J.Pharmacol.Exp.Ther.2012,343,556-567;J.Med.Chem.2014,57,8035-8055)。尽管如此,PX-104的体外活性仍有进一步提升的空间,临床剂量相对较高。因此,持续地需要激动FXR的新型或改进的药物,以用于开发新的、更有效的药物来治疗NASH、NAFLD、PBC或其它与FXR相关的疾病。
发明内容
本发明人经过潜心研究,设计合成了一系列含有桥环基取代的芳环或芳杂环骨架的化合物,并对其进行了FXR活性的筛选,研究结果显示该类化合物具有突出的FXR激动活性,并且可以被开发为治疗与FXR活性相关的疾病的药物。
因此,本发明的目的为提供一种通式(I)所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,
其中:
其中,X为CH、CF、N或NO;
R2选自氢、卤素、烷基、环烷基,其中所述烷基或环烷基任选进一步被选自卤素、羟基、烷基、烷氧基的一个或多个基团所取代;
R3和R4各自独立地选自氢、卤素、烷基、烷氧基,所述烷基或烷氧基任选进一步被一个或多个卤素取代;
Ar为5元或6元芳基或杂芳基;
Cy为芳基或杂芳基;
R1选自-(CH2)m-R5或-O(CH2)m-R5;其中所述-(CH2)m-或-O(CH2)m-基团任选进一步被选自卤素、氰基、羟基、氧代基、烷基、卤代烷基、烷氧基、卤代烷氧基、CO2H、SO3H的一个或多个基团取代;
R5选自氢、卤素、氰基、硝基、烷基、环烷基、杂环基、芳基、杂芳基、OR6、NR6R7、-CO2R6、-C(O)R6、-C(O)NR6R7、-N(R6)C(O)R7、-C(O)NR6SO2R7、-S(O)pR6、-S(O)pNR6R7、-N(R6)S(O)pR7、或-S(O)pNR6COR7;所述烷基、环烷基、杂环基、芳基或杂芳基任选进一步被选自卤素、氨基、硝基、氰基、羟基、巯基、羧基、酯基、氧代基、烷基、卤代烷基、烷氧基、卤代烷氧基、烯基、炔基、环烷基、卤代环烷基、杂环基、芳基、杂芳基的一个或多个基团取代;
R6和R7各自独立地选自氢、卤素、羟基、烷基、环烷基、杂环基、芳基、杂芳基,其中所述烷基、环烷基、杂环基、芳基和杂芳基任选进一步被选自卤素、氨基、硝基、氰基、羟基、巯基、羧基、酯基、氧代基、烷基、烷氧基、环烷基、杂环基、芳基、杂芳基的一个或多个基团取代;
或者R6和R7与他们连接的氮原子一起形成含氮杂环基,所述含氮杂环基任选进一步被选自卤素、氨基、硝基、氰基、氧代基、羟基、巯基、羧基、酯基、烷基、烷氧基、环烷基、杂环基、芳基、杂芳基的一个或多个基团取代;
每一个R8可以相同或不同,且各自独立地选自卤素、氨基、硝基、氰基、羟基、巯基、羧基、酯基、烷基、卤代烷基、烷氧基、卤代烷氧基、烯基、炔基、环烷基、卤代环烷基、杂环基、芳基、杂芳基;
n为0、1或2;
m为0至6的整数;
p为0、1或2;
q为0至4的整数;
在本发明一个优选的实施方案中,根据本发明所述的通式(I)所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,其为通式(II)所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,
其中,
X1、X2、X3各自独立地选自C、N、O或S,优选N,O;
Z、n、Cy、R1、R8、q如通式(I)所定义。
在本发明另一个优选的实施方案中,根据本发明所述的通式(I)所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,
其中,Ar选自噁唑、异噁唑、噻唑、异噻唑、咪唑、三氮唑、1,2,3-噁二唑、1,2,4-噁二唑、1,3,4-噁二唑、1,2,3-噻二唑、1,2,4-噻二唑或1,3,4-噻二唑。
在本发明另一个优选的实施方案中,根据本发明所述的通式(I)所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,
其中,
X选自CH或N;
R2选自氢、卤素、烷基、环烷基,优选C1-C6烷基或C3-C6环烷基,更优选环丙基;所述烷基或环烷基任选进一步被选自卤素、羟基、烷基、烷氧基的一个或多个基团所取代;
R3和R4各自独立地选自氢、卤素、烷基、卤代烷基、烷氧基、卤代烷氧基,优选氢、卤素、C1-C6卤代烷基和C1-C6卤代烷氧基。
在本发明另一个优选的实施方案中,根据本发明所述的通式(I)所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,
其中,n为1。
在本发明另一个优选的实施方案中,根据本发明所述的通式(I)所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,
其中,
Cy为C5-C6芳基或5至6元杂芳基,优选苯基、吡啶基、嘧啶基、吡嗪基、噻唑基、呋喃基、咪唑基、吡唑基。
在本发明另一个优选的实施方案中,根据本发明所述的通式(I)所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,
其中,
R1选自-(CH2)m-R5或-O(CH2)m-R5;
R5选自氢、卤素、烷基、OR6、NR6R7、-CO2R6、-C(O)R6、-C(O)NR6R7、-N(R6)C(O)R7、-C(O)NR6SO2R7、-S(O)pR6、-S(O)pNR6R7、-N(R6)S(O)pR7、或-S(O)pNR6COR7,优选-C(O)R6、-C(O)NR6R7、-S(O)pR6、-S(O)pNR6R7,更优选-C(O)R6或-S(O)pNR6R7,甚至更优选-COOH;
R6和R7各自独立地选自氢、卤素、羟基、烷基、环烷基、杂环基、芳基、杂芳基,其中所述烷基、环烷基、杂环基、芳基和杂芳基任选进一步被选自卤素、氨基、硝基、氰基、羟基、巯基、羧基、酯基、氧代基、烷基、烷氧基、环烷基、杂环基、芳基、杂芳基的一个或多个基团取代;
或者R6和R7与他们连接的氮原子一起形成含氮杂环基,所述含氮杂环基任选进一步被选自卤素、氨基、硝基、氰基、氧代基、羟基、巯基、羧基;
m为0至6的整数,优选0、1或2;更优选0。
在本发明另一个优选的实施方案中,根据本发明所述的通式(I)所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,
其中,
每一个R8可以相同或不同,且各自独立地选自卤素、烷基、卤代烷基、烷氧基、卤代烷氧基;
q为0至4的整数;优选q为0或1。
本发明典型的化合物包括但不限于:
4-(5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)-异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,2,4-噁二唑-3-基)苯甲酸;
2-氯-4-(5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛-8-基)-1,2,4-噁二唑-3-基)苯甲酸;
6-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,2,4-噁二唑-3-基)吡啶-2-甲酸;
5-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,2,4-噁二唑-3-基)噻吩-2-甲酸;
4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,2,4-噁二唑-3-基)-3-甲基苯甲酸;
3-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,2,4-噁二唑-3-基)苯甲酸;
4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,2,4-噁二唑-3-基)-2-甲基苯甲酸;
4-(5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛-8-基)-1,3,4-噁二唑-2-基)苯甲酸;
2-氯-4-(5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛-8-基)-1,3,4-噁二唑-2-基)苯甲酸;
6-(5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)吡啶-2-甲酸;
5-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)噻吩-2-甲酸;
4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-2-氟苯甲酸;
4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-2-甲氧基苯甲酸;
4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-3-甲基苯甲酸;
3-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)苯甲酸;
4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-3-氟苯甲酸;
4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-2-甲基苯甲酸;
5-(5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)吡啶甲酸;
6-(5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)烟酸;
5-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)噻吩-3-羧酸;
4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)噻吩-2-羧酸;
4-(5-((1R,3r,5S)-3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛-8-基)-1,3,4-噁二唑-2-基)苯甲酸;
2-氯-4-(5-((1R,3r,5S)-3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛-8-基)-1,3,4-噁二唑-2-基)苯甲酸;
6-(5-((1R,3r,5S)-3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)吡啶-2-甲酸;
5-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)噻吩-2-甲酸;
4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-2-氟苯甲酸;
4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-3-甲基苯甲酸;
3-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)苯甲酸;
4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-3-氟苯甲酸;
4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-2-甲基苯甲酸;
5-(5-((1R,3r,5S)-3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)吡啶甲酸;
6-(5-((1R,3r,5S)-3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)烟酸;
5-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)噻吩-3-羧酸;
4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)噻吩-2-羧酸;
或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐。
本发明进一步提供一种制备根据本发明所述的通式(I)所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐的方法,其包括以下步骤:
在缩合剂条件下,将化合物IE与ID进行环合反应得到通式(I)化合物,其中,缩合剂优选氯化锌;
其中,Z、n、Cy、R1、R8、q如通式(I)所定义。
本发明进一步提供一种制备根据本发明所述的通式(I)所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐的方法,其包括以下步骤:
在氧化剂条件下,将化合物IJ进行环合反应得到通式(I)化合物,其中,氧化剂优选碘苯二乙酸;
其中,Z、n、Cy、R1、R8、q如通式(I)所定义。
本发明另一方面提供一种药物组合物,其含有根据本发明所述的通式(I)所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,以及药学上可接受的载体。
本发明进一步提供根据本发明所述的通式(I)所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,或者含有其的药物组合物,在制备FXR激动剂中的用途。
本发明进一步提供根据本发明所述的通式(I)所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,或者含有其的药物组合物,在制备预防和/或治疗与FXR活性相关的疾病的药物中的用途。
本发明提供根据本发明所述的通式(I)所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,或者含有其的药物组合物,其用作FXR激动剂的用途。
本发明进一步提供根据本发明所述的通式(I)所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,或者含有其的药物组合物,其用作药物的用途,所述药物用于预防和/或治疗与FXR活性相关的疾病。
本发明进一步提供一种预防和/或治疗与FXR活性相关的疾病的方法,其包括向有需要的受试者施用预防或治疗有效量的根据本发明所述的通式(I)所示的化合物或其内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、其前药或其可药用盐,或者含有其的药物组合物。
在本发明的一个优选的实施方案中,根据本发明所述的与FXR活性相关的疾病可以为:慢性肝内胆汁郁积病症或肝外胆汁郁积病症,或慢性胆汁郁积病症或急性肝内胆汁郁积病症导致的肝纤维化;和/或肝脏梗阻性或慢性炎症;和/或肝硬化;和/或肝皮脂腺病和相关的综合征,与酒精诱导的肝硬变或与病毒性肝炎相关的胆汁郁积或纤维变性作用;和/或肝脏切除后的肝脏衰竭或肝脏缺血;和/或脂肪肝炎相关的化学疗法;和/或急性肝脏衰竭;和/或炎性肠病;和/或脂质和脂质蛋白紊乱;和/或糖尿病及糖尿病临床并发症,包括糖尿病性肾病、糖尿病性神经病、糖尿病视网膜病和其他临床表现;和/或脂质,特别是甘油三酯蓄积,及甘油三酯蓄积导致的慢性脂肪和纤维变性引起的疾病和病症,例如非酒精性脂肪肝或非酒精性脂肪肝炎;和/或肥胖或代谢综合征,例如血脂障碍、糖尿病、体重指数异常高的合并病症;和/或作为慢性梗阻性动脉粥样硬化终末点而产生的急性心肌梗塞、急性中风、或血栓形成;非恶性过度增殖性疾病和恶性过度增殖性疾病,特别是肝细胞癌、结肠腺瘤和息肉病、结肠腺癌、乳腺癌、胰腺癌、巴特氏食管癌和其他形式的胃肠道和肝脏肿瘤性疾病。
按照本发明所属领域的常规方法,本发明通式(I)所示的化合物可以与酸生成药学上可接受的酸式加成盐。所述酸包括无机酸和有机酸,特别优选盐酸、氢溴酸、硫酸、磷酸、甲磺酸、乙磺酸、对甲苯磺酸、苯磺酸、萘二磺酸、乙酸、丙酸、乳酸、三氟乙酸、马来酸、柠檬酸、富马酸、草酸、酒石酸、苯甲酸等。
按照本发明所属领域的常规方法,本发明通式(I)所示的化合物可以与碱生成药学上可接受的碱式加成盐。所述碱包括无机碱和有机碱,可接受的有机碱包括二乙醇胺、乙醇胺、N-甲基葡糖胺、三乙醇胺、氨丁三醇等,可接受的无机碱包括氢氧化铝、氢氧化钙、氢氧化钾、碳酸钠和氢氧化钠等。
此外,本发明还包括本发明通式(I)所示的化合物的前药。本发明所述的前药是通式(I)所示的化合物的衍生物,它们自身可能具有较弱的活性甚至没有活性,但是在给药后,在生理条件下(例如通过代谢、溶剂分解或另外的方式)被转化成相应的生物活性形式。
含活性成分的药物组合物可以是适用于口服的形式,例如片剂、糖锭剂、锭剂、水或油混悬液、可分散粉末或颗粒、乳液、硬或软胶囊,或糖浆剂或酏剂。可按照本领域任何已知制备药用组合物的方法制备口服组合物,此类组合物可含有一种或多种选自以下的成分:甜味剂、矫味剂、着色剂和防腐剂,以提供悦目和可口的药用制剂。片剂含有活性成分和用于混合的适宜制备片剂的无毒的可药用的赋形剂。这些赋形剂可以是惰性赋形剂,如碳酸钙、碳酸钠、乳糖、磷酸钙或磷酸钠;造粒剂和崩解剂,例如微晶纤维素、交联羧甲基纤维素钠、玉米淀粉或藻酸;粘合剂,例如淀粉、明胶、聚乙烯吡咯烷酮或阿拉伯胶;和润滑剂,例如硬脂酸镁、硬脂酸或滑石粉。这些片剂可以不包衣或可通过掩盖药物的味道或在胃肠道中延迟崩解和吸收,因而在较长时间内提供缓释作用的已知技术将其包衣。例如,可使用水溶性味道掩蔽物质,例如羟丙基甲基纤维素或羟丙基纤维素,或延长时间物质例如乙基纤维素、醋酸丁酸纤维素。
也可用其中活性成分与惰性固体稀释剂例如碳酸钙、磷酸钙或高岭土混合的硬明胶胶囊,或其中活性成分与水溶性载体例如聚乙二醇或油溶媒例如花生油、液体石蜡或橄榄油混合的软明胶胶囊提供口服制剂。
水混悬液含有活性物质和用于混合的适宜制备水混悬液的赋形剂。此类赋形剂是悬浮剂,例如羧基甲基纤维素钠、甲基纤维素、羟丙基甲基纤维素、藻酸钠、聚乙烯吡咯烷酮和阿拉伯胶;分散剂或湿润剂,可以是天然产生的磷脂例如卵磷脂,或烯化氧与脂肪酸的缩合产物,例如聚氧乙烯硬脂酸酯,或环氧乙烷与长链脂肪醇的缩合产物,例如十七碳亚乙基氧基鲸蜡醇(heptadecaethyleneoxy cetanol),或环氧乙烷与由脂肪酸和己糖醇衍生的部分酯的缩合产物,例如聚环氧乙烷山梨醇单油酸酯,或环氧乙烷与由脂肪酸和己糖醇酐衍生的偏酯的缩合产物,例如聚环氧乙烷脱水山梨醇单油酸酯。水混悬液也可以含有一种或多种防腐剂例如尼泊金乙酯或尼泊金正丙酯、一种或多种着色剂、一种或多种矫味剂和一种或多种甜味剂,例如蔗糖、糖精或阿司帕坦。
油混悬液可通过使活性成分悬浮于植物油如花生油、橄榄油、芝麻油或椰子油,或矿物油例如液体石蜡中配制而成。油混悬液可含有增稠剂,例如蜂蜡、硬石蜡或鲸蜡醇。可加入上述的甜味剂和矫味剂,以提供可口的制剂。可通过加入抗氧化剂例如丁羟茴醚或α-生育酚保存这些组合物。
通过加入水,适用于制备水混悬液的可分散粉末和颗粒可以提供活性成分和用于混合的分散剂或湿润剂、悬浮剂或一种或多种防腐剂。适宜的分散剂或湿润剂和悬浮剂如上所述。也可加入其他赋形剂例如甜味剂、矫味剂和着色剂。通过加入抗氧化剂例如抗坏血酸保存这些组合物。
本发明的药物组合物也可以是水包油乳剂的形式。油相可以是植物油例如橄榄油或花生油,或矿物油例如液体石蜡或其混合物。适宜的乳化剂可以是天然产生的磷脂,例如大豆卵磷脂,和由脂肪酸和己糖醇酐衍生的酯或偏酯,例如山梨坦单油酸酯,和所述偏酯和环氧乙烷的缩合产物,例如聚环氧乙烷山梨醇单油酸酯。乳剂也可以含有甜味剂、矫味剂、防腐剂和抗氧剂。可用甜味剂例如甘油、丙二醇、山梨醇或蔗糖配制的糖浆和酏剂。此类制剂也可含有缓和剂、防腐剂、着色剂和抗氧剂。
本发明的药物组合物可以是无菌注射水溶液形式。可以使用的可接受的溶媒和溶剂有水、林格氏液和等渗氯化钠溶液。无菌注射制剂可以是其中活性成分溶于油相的无菌注射水包油微乳。例如将活性成分溶于大豆油和卵磷脂的混合物中。然后将油溶液加入水和甘油的混合物中处理形成微乳。可通过局部大量注射,将注射液或微乳注入患者的血流中。或者,最好按可保持本发明化合物恒定循环浓度的方式给予溶液和微乳。为保持这种恒定浓度,可使用连续静脉内递药装置。
本发明的药物组合物可以是用于肌内和皮下给药的无菌注射水或油混悬液的形式。可按已知技术,用上述那些适宜的分散剂或湿润剂和悬浮剂配制该混悬液。无菌注射制剂也可以是在无毒肠胃外可接受的稀释剂或溶剂中制备的无菌注射溶液或混悬液,例如在1,3-丁二醇中制备的溶液。此外,可方便地用无菌固定油作为溶剂或悬浮介质。为此目的,可使用包括合成甘油单或二酯在内的任何调和固定油。此外,脂肪酸例如油酸也可以制备注射剂。
可按用于直肠给药的栓剂形式给予本发明化合物。可通过将药物与在普通温度下为固体但在直肠中为液体,因而在直肠中会溶化而释放药物的适宜的无刺激性赋形剂混合来制备这些药物组合物。此类物质包括可可脂、甘油明胶、氢化植物油、各种分子量的聚乙二醇和聚乙二醇的脂肪酸酯的混合物。
本领域技术人员熟知,药物的给药剂量依赖于多种因素,包括但并非限定于以下因素:所用特定化合物的活性、病人的年龄、病人的体重、病人的健康状况、病人的行被、病人的饮食、给药时间、给药方式、排泄的速率、药物的组合等。另外,最佳的治疗方式如治疗的模式、通式化合物的日用量或可药用的盐的种类可以根据传统的治疗方案来验证。
本发明可以含有通式(I)所示的化合物,及其药学上可接受的盐、水合物或溶剂化物作为活性成分,与药学上可接受的载体或赋型剂混合制备成组合物,并制备成临床上可接受的剂型。本发明的衍生物可以与其他活性成分组合使用,只要它们不产生其他不利的作用,例如过敏反应等。本发明化合物可作为唯一的活性成分,也可以与其它治疗与FXR活性相关的疾病的药物联合使用。联合治疗通过将各个治疗组分同时、分开或相继给药来实现。
发明的详细说明
除非有相反陈述,在说明书和权利要求书中使用的术语具有下述含义。
术语“烷基”指饱和脂肪族烃基团,其为包含1至20个碳原子的直链或支链基团,优选含有1至12个碳原子的烷基,更优选含有1至6个碳原子的烷基。非限制性实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基、正庚基、2-甲基己基、3-甲基己基、4-甲基己基、5-甲基己基、2,3-二甲基戊基、2,4-二甲基戊基、2,2-二甲基戊基、3,3-二甲基戊基、2-乙基戊基、3-乙基戊基、正辛基、2,3-二甲基己基、2,4-二甲基己基、2,5-二甲基己基、2,2-二甲基己基、3,3-二甲基己基、4,4-二甲基己基、2-乙基己基、3-乙基己基、4-乙基己基、2-甲基-2-乙基戊基、2-甲基-3-乙基戊基、正壬基、2-甲基-2-乙基己基、2-甲基-3-乙基己基、2,2-二乙基戊基、正癸基、3,3-二乙基己基、2,2-二乙基己基,及其各种支链异构体等。更优选的是含有1至6个碳原子的低级烷基,非限制性实施例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基等。烷基可以是取代的或非取代的,当被取代时,取代基可以在任何可使用的连接点上被取代,所述取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基。
术语“烯基”指由至少由两个碳原子和至少一个碳-碳双键组成的如上定义的烷基,例如乙烯基、1-丙烯基、2-丙烯基、1-、2-或3-丁烯基等。烯基可以是取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“炔基”指由至少由两个碳原子和至少一个碳-碳三键组成的如上定义的烷基,例如乙炔基、丙炔基、丁炔基等。炔基可以是取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“环烷基”指饱和或部分不饱和单环或多环环状烃取代基,环烷基环包含3至20个碳原子,优选包含3至12个碳原子,更优选包含3至6个碳原子。单环环烷基的非限制性实例包括环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环庚基、环庚三烯基、环辛基等;多环环烷基包括螺环、稠环和桥环的环烷基。
术语“螺环烷基”指5至20元的单环之间共用一个碳原子(称螺原子)的多环基团,其可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统。优选为6至14元,更优选为7至10元。根据环与环之间共用螺原子的数目将螺环烷基分为单螺环烷基、双螺环烷基或多螺环烷基,优选为单螺环烷基和双螺环烷基。更优选为4元/4元、4元/5元、4元/6元、5元/5元或5元/6元单螺环烷基。螺环烷基的非限制性实例包括:
术语“稠环烷基”指5至20元,系统中的每个环与体系中的其他环共享毗邻的一对碳原子的全碳多环基团,其中一个或多个环可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统。优选为6至14元,更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环稠环烷基,优选为双环或三环,更优选为5元/5元或5元/6元双环烷基。稠环烷基的非限制性实例包括:
术语“桥环烷基”指5至20元,任意两个环共用两个不直接连接的碳原子的全碳多环基团,其可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统。优选为6至14元,更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环桥环烷基,优选为双环、三环或四环,更有选为双环或三环。桥环烷基的非限制性实例包括:
所述环烷基环可以稠合于芳基、杂芳基或杂环烷基环上,其中与母体结构连接在一起的环为环烷基,非限制性实例包括茚满基、四氢萘基、苯并环庚烷基等。环烷基可以是任选取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基。
术语“杂环基”指饱和或部分不饱和单环或多环环状烃取代基,其包含3至20个环原子,其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子,但不包括-O-O-、-O-S-或-S-S-的环部分,其余环原子为碳。优选包含3至12个环原子,其中1~4个是杂原子;最优选包含3至8个环原子,其中1~3个是杂原子;最优选包含5至7个环原子,其中1~2或1~3个是杂原子。单环杂环基的非限制性实例包括吡咯烷基、咪唑烷基、四氢呋喃基、四氢噻吩基、二氢咪唑基、二氢呋喃基、二氢吡唑基、二氢吡咯基、哌啶基、哌嗪基、吗啉基、硫代吗啉基、高哌嗪基、吡喃基等,优选1、2、5-噁二唑基、吡喃基或吗啉基。多环杂环基包括螺环、稠环和桥环的杂环基。
术语“螺杂环基”指5至20元的单环之间共用一个原子(称螺原子)的多环杂环基团,其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子,其余环原子为碳。其可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统。优选为6至14元,更优选为7至10元。根据环与环之间共用螺原子的数目将螺杂环基分为单螺杂环基、双螺杂环基或多螺杂环基,优选为单螺杂环基和双螺杂环基。更优选为4元/4元、4元/5元、4元/6元、5元/5元或5元/6元单螺杂环基。螺杂环基的非限制性实例包括:
术语“稠杂环基”指5至20元,系统中的每个环与体系中的其他环共享毗邻的一对原子的多环杂环基团,一个或多个环可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统,其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子,其余环原子为碳。优选为6至14元,更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环稠杂环基,优选为双环或三环,更优选为5元/5元或5元/6元双环稠杂环基。稠杂环基的非限制性实例包括:
术语“桥杂环基”指5至14元,任意两个环共用两个不直接连接的原子的多环杂环基团,其可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统,其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子,其余环原子为碳。优选为6至14元,更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环桥杂环基,优选为双环、三环或四环,更有选为双环或三环。桥杂环基的非限制性实例包括:
所述杂环基环可以稠合于芳基、杂芳基或环烷基环上,其中与母体结构连接在一起的环为杂环基,其非限制性实例包括:
杂环基可以是任选取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基。
术语“芳基”指具有共轭的π电子体系的6至14元全碳单环或稠合多环(也就是共享毗邻碳原子对的环)基团,优选为6至10元,例如苯基和萘基。更优选苯基。所述芳基环可以稠合于杂芳基、杂环基或环烷基环上,其中与母体结构连接在一起的环为芳基环,其非限制性实例包括:
芳基可以是取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“杂芳基”指包含1至4个杂原子、5至14个环原子的杂芳族体系,其中杂原子选自氧、硫和氮。杂芳基优选为5至10元,含1至3个杂原子;更优选为5元或6元,含1至2个杂原子;优选例如咪唑基、呋喃基、噻吩基、噻唑基、吡唑基、噁唑基、吡咯基、四唑基、吡啶基、嘧啶基、噻二唑、吡嗪基等,优选为咪唑基、噻唑基、吡唑基或嘧啶基、噻唑基;更有选吡唑基或噻唑基。所述杂芳基环可以稠合于芳基、杂环基或环烷基环上,其中与母体结构连接在一起的环为杂芳基环,其非限制性实例包括:
杂芳基可以是任选取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“烷氧基”指-O-(烷基)和-O-(非取代的环烷基),其中烷基的定义如上所述。烷氧基的非限制性实例包括:甲氧基、乙氧基、丙氧基、丁氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基。烷氧基可以是任选取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“卤代烷基”指被一个或多个卤素取代的烷基,其中烷基如上所定义。
术语“卤代烷氧基”指被一个或多个卤素取代的烷氧基,其中烷氧基如上所定义。
术语“羟烷基”指被羟基取代的烷基,其中烷基如上所定义。
术语“羟基”指-OH基团。
术语“卤素”指氟、氯、溴或碘。
术语“氨基”指-NH2。
术语“氰基”指-CN。
术语“硝基”指-NO2。
术语“氧代基”指=O。
术语“羧基”指-C(O)OH。
术语“巯基”指-SH。
术语“酯基”指-C(O)O(烷基)或-C(O)O(环烷基),其中烷基和环烷基如上所定义。
术语“酰基”指含有-C(O)R基团的化合物,其中R为烷基、环烷基、杂环基、芳基、杂芳基。
术语“磺酸基”指-S(O)2OH。
术语“磺酸酯基”指-S(O)2O(烷基)或-S(O)2O(环烷基),其中烷基和环烷基如上所定义。
术语“磺酰基”指-S(O)2R基团的化合物,其中R为烷基、环烷基、杂环基、芳基、杂芳基。
术语“氨基酰基”指-C(O)-NRR’,其中R、R’各自独立地为氢、烷基、环烷基、杂环基、芳基、杂芳基。
术语“氨基磺酰基”或“磺酰氨基”指-S(O)2-NRR’,其中R、R’各自独立地为氢、烷基、环烷基、杂环基、芳基、杂芳基。
“任选”或“任选地”意味着随后所描述的事件或环境可以但不必发生,该说明包括该事件或环境发生或不发生的场合。例如,“任选被烷基取代的杂环基团”意味着烷基可以但不必须存在,该说明包括杂环基团被烷基取代的情形和杂环基团不被烷基取代的情形。
“取代的”指基团中的一个或多个氢原子,优选为最多5个,更优选为1~3个氢原子彼此独立地被相应数目的取代基取代。不言而喻,取代基仅处在它们的可能的化学位置,本领域技术人员能够在不付出过多努力的情况下确定(通过实验或理论)可能或不可能的取代。例如,具有游离氢的氨基或羟基与具有不饱和(如烯属)键的碳原子结合时可能是不稳定的。
“药物组合物”表示含有一种或多种本文所述化合物或其生理学上/可药用的盐或前体药物与其他化学组分的混合物,以及其他组分例如生理学/可药用的载体和赋形剂。药物组合物的目的是促进对生物体的给药,利于活性成分的吸收进而发挥生物活性。
“可药用盐”是指本发明化合物的盐,这类盐用于哺乳动物体内时具有安全性和有效性,且具有应有的生物活性。
本发明化合物的合成方法
为了完成本发明的目的,本发明采用如下技术方案。
本发明通式(I)所示的化合物或其盐可通过以下方案制备,具体制备方法如下。
方案1
方案1的合成:
在碱性条件下,将化合物IA与Z-CH2-Br反应得到化合物IB,其中,碱性试剂优选叔丁醇钾;随后,将化合物IB在酸性条件下发生脱保护反应得到化合物IC,其中,酸性试剂优选三氟乙酸;随后,在碱性条件下,将化合物IC与溴化氰反应得到化合物ID,其中,碱性试剂优选碳酸钾;随后,在缩合剂条件下,将化合物ID与IE发生缩合关环反应,得到通式(II)化合物,其中,缩合剂优选氯化锌。
其中,Z、n、Cy、R1、R8、q如通式(I)所定义。
方案2
方案2的合成:
在碱性条件和缩合剂的作用下,将化合物IF与肼基甲酸叔丁酯发生缩合反应得到化合物IG,其中,碱性试剂优选DMAP,缩合剂优选EDC;随后,将化合物IG在酸性条件下发生脱保护反应得到化合物IH,其中,酸性试剂优选三氟乙酸;随后,化合物IH与原甲酸三乙酯发生环合反应,得到化合物II;随后,在碱性条件下,将化合物II与IC发生缩合反应,得到化合物IJ,其中,碱性条件优选三乙胺;最后,在氧化剂条件下,将化合物IJ进行环合反应得到通式(I)化合物,氧化剂优选碘苯二乙酸。
其中,Z、n、Cy、R1、R8、q如通式(I)所定义。
具体实施方式
以下结合实施例进一步描述本发明,但这些实施例并非限制着本发明的范围。
化合物的结构是通过核磁共振(NMR)或/和质谱(MS)来确定的。NMR位移以10-6(ppm)的单位给出。NMR的测定是用Brukerdps300型核磁仪,测定溶剂为氘代二甲基亚砜(DMSO-d6)、氘代氯仿(CDCl3)、氘代甲醇(CD3OD),内标为四甲基硅烷(TMS)。
MS的测定用1100 Series LC/MSD Trap(ESI)质谱仪(生产商:Agilent)。
制备液相使用lc3000高效液相色谱仪以及lc6000高效液相色谱仪(生产商:创新通恒)。色谱柱为Daisogel C18 10μm 60A(20mm×250mm)。
HPLC的测定使用岛津LC-20AD高压液相色谱仪(Agilent TC-C18 250×4.6mm5μm色谱柱)和岛津LC-2010AHT高压液相色谱仪(Phenomenex C18 250×4.6mm5μm色谱柱)。
薄层层析硅胶板使用青岛海洋化工GF254硅胶板,薄层色谱法(TLC)使用的硅胶板采用的规格是0.15mm~0.2mm,薄层层析分离纯化产品采用的规格是0.4mm~0.5mm。
柱层析一般使用青岛海洋硅胶100~200目、200~300目硅胶为载体。
本发明的已知的起始原料可以采用或按照本领域已知的方法来合成,或可购买自网化商城、北京耦合、Sigma、百灵威、易世明、上海书亚、伊诺凯、南京药石、安耐吉化学等公司。
实施例中无特殊说明,反应能够均在氩气氛或氮气氛下进行。
氩气氛或氮气氛是指反应瓶连接一个约1L容积的氩气或氮气气球。
微波反应使用CEM Discover SP型微波反应器。
实施例中无特殊说明,溶液是指水溶液。
实施例中无特殊说明,反应的温度为室温,为20℃~30℃。
实施例中的反应进程的监测采用薄层色谱法(TLC),反应所使用的展开剂的体系有:A:二氯甲烷和甲醇体系,B:正己烷和乙酸乙酯体系,C:石油醚和乙酸乙酯体系,D:丙酮,溶剂的体积比根据化合物的极性不同而进行调节。
纯化化合物采用的柱层析的洗脱剂的体系和薄层色谱法的展开剂体系包括:A:二氯甲烷和甲醇体系,B:石油醚、乙酸乙酯和二氯甲烷体系,C:石油醚和乙酸乙酯体系,溶剂的体积比根据化合物的极性不同而进行调节,也可以加入少量的三乙胺和醋酸等碱性或酸性试剂进行调节。
实施例1:4-(5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)-异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,2,4-噁二唑-3-基)苯甲酸(1)的制备
步骤1:(1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂二环[3.2.1]辛烷-8-羧酸叔丁酯(1B)的制备
将18-冠醚-6(4.95g,18.7mmol)、(1R,3r,5S)-3-羟基-8-氮杂二环[3.2.1]辛烷-8-羧酸叔丁酯(4.24g,18.7mmol)、THF(90mL)加入至反应瓶中,降温至0℃。向上述混合物中加入叔丁醇钾(2.86g,25.5mmol),于0℃搅拌5分钟后,将4-(溴甲基)-5-环丙基-3-(2,6-二氯苯基)异噁唑(根据文献WO2011020615公开的方法制备)(5.90g,17mmol)溶解于10mLTHF中,缓慢滴加至以上混合物中,滴加完毕后,继续室温搅拌2小时。反应完成后,向反应液中加入乙酸乙酯(100mL)和水(100mL),有机相用饱和食盐水、水各洗涤一次,无水硫酸钠干燥,过滤,滤液减压浓缩,得到9.20g黄色油状的标题产物粗品,直接用于下一步。
步骤2:4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2,6-二氯苯基)异噁唑(1C)的制备
将(1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂二环[3.2.1]辛烷-8-羧酸叔丁酯(9.20g,18.7mmol)、二氯甲烷(36mL)、三氟乙酸(18mL)加入至反应瓶中,室温搅拌1小时。反应完成后,用碳酸氢钠水溶液、水各洗涤一次,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物通过硅胶柱层析色谱法(洗脱剂:二氯甲烷-二氯甲烷∶甲醇=10∶1)纯化,得到4.00g黄色固体状的标题产物,收率:54.6%。
步骤3:(1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-甲腈(1D)的制备
将4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2,6-二氯苯基)异噁唑(4.00g,10.24mmol)、水(80mL)、碳酸钾(4.30g,30.72mmol)加入至反应瓶中,室温搅拌下将溴化氰(1.20g,11.27mmol)加入至80mL二氯甲烷中,缓慢滴加到反应瓶中,滴加完毕后,继续室温搅拌2小时。反应完成后,用1N盐酸水溶液(90mL)、水(90mL)各洗涤一次,无水硫酸钠干燥,过滤,滤液减压浓缩,得到4.00g黄色油状物的标题产物,收率:94.0%。
步骤4:4-(5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,2,4-噁二唑-3-基)苯甲酸甲酯(1E)的制备
将对氰基苯甲酸甲酯(2.00g,12.4mmol)、甲醇(40mL)、盐酸羟胺(0.87g,12.4mmol)、碳酸氢钠(1.13g,13.4mmol)加入至反应瓶中,室温搅拌0.5小时后,升温至75℃继续搅拌3小时。反应完成后,将反应液倾倒入50mL冰水中,搅拌10分钟,过滤,滤饼用水洗涤,干燥得1.50g白色固体状的4-(N-羟基甲脒基)苯甲酸甲酯,收率62.2%。
将4-(N-羟基甲脒基)苯甲酸甲酯(1.00g,2.4mmol)、乙酸乙酯(30mL)、0.5N氯化锌的四氢呋喃溶液(18mL)和(1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-甲腈(1.00g,5.15mmol)加入至反应瓶中,于50℃搅拌3小时,然后升温至70℃继续搅拌18小时。反应完成后,向反应液中加入水(100mL)和乙酸乙酯(100mL),有机相用水、饱和食盐水各洗涤一次,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物通过硅胶柱层析色谱法纯化(洗脱剂:正庚烷∶乙酸乙酯=5∶1),得0.60g白色固体状标题产物,收率42.1%。
步骤5:4-(5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,2,4-噁二唑-3-基)苯甲酸(1)的制备
将4-(5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,2,4-噁二唑-3-基)苯甲酸甲酯(0.60g,1mmol)、甲醇(30mL)、2N氢氧化钾水溶液(10mL)加入至反应瓶中,于40℃搅拌18小时。反应完成后,加入100mL水,用盐酸调节至pH=2~3,析出黄色固体,过滤,干燥得580mg黄色固体,经制备液相色谱法(洗脱剂:0%-100%乙腈:水溶液)纯化,得到278mg浅黄色固体状标题产物,收率47.5%。
MS:m/z=581.4[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.14(m,2H),1.27(m,2H),1.81(m,2H),2.00(m,6H),2.33(m,1H),3.55(s,1H),4.28(s,2H),4.37(m,2H),7.36(m,1H),7.43(m,2H),8.11(m,2H),8.17(m,2H)。
实施例2:2-氯-4-(5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛-8-基)-1,2,4-噁二唑-3-基)苯甲酸(2)的制备
与实施例1的制备方法相同,除了用2-氯-4-氰基苯甲酸甲酯替代对氰基苯甲酸甲酯,制得标题化合物2。
MS:m/z=615.2[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,2H),1.28(m,2H),1.68(m,2H),1.75(m,4H),1.94(m,2H),2.35(m,1H),3.50(m,1H),4.06(m,2H),4.38(s,2H),7.63(m,3H),7.92(m,1H),8.06(m,2H)。
实施例3:6-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,2,4-噁二唑-3-基)吡啶-2-甲酸(3)的制备
与实施例1的制备方法相同,除了用6-氰基吡啶-2-羧酸甲酯代替对氰基苯甲酸甲酯,制得标题化合物3。
MS:m/z=582.2[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,4H),1.64(m,2H),1.80(m,4H),1.94(m,2H),2.36(m,1H),3.52(m,1H),4.29(m,2H),4.37(s,2H),7.80(m,3H),8.27(m,3H)。
实施例4:5-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,2,4-噁二唑-3-基)噻吩-2-甲酸(4)的制备
与实施例1的制备方法相同,除了用5-氰基噻吩-2-甲酸甲酯替代对氰基苯甲酸甲酯,制得标题化合物4。
MS:m/z=587.1[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.16(m,2H),1.28(m,2H),1.66(m,2H),1.74(m,4H),1.85(m,2H),2.34(m,1H),3.54(m,1H),4.22(m,2H),4.28(s,2H),7.64(m,3H),7.79(m,1H),7.90(m,1H)。
实施例5:4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,2,4-噁二唑-3-基)-3-甲基苯甲酸(5)的制备
与实施例1的制备方法相同,除了用4-氰基-3-甲基苯甲酸甲酯替代对氰基苯甲酸甲酯,制得标题化合物5。
MS:m/z=595.4[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.12(m,2H),1.28(m,2H),1.78(m,2H),1.86(m,4H),1.91(m,2H),2.31(m,1H),2.65(s,3H),3.58(m,1H),4.06(m,2H),4.26(s,2H),7.58(m,1H),7.66(m,2H),7.93(m,2H),8.05(m,1H)。
实施例6:3-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,2,4-噁二唑-3-基)苯甲酸(6)的制备
与实施例1的制备方法相同,除了用间氰基苯甲酸甲酯替代对氰基苯甲酸甲酯,制得标题化合物6。
MS:m/z=581.1[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,4H),1.59(m,2H),1.68(m,4H),1.98(m,2H),2.31(m,1H),2.65(s,3H),3.48(m,1H),4.07(m,2H),4.28(s,2H),7.59(m,3H),7.75(m,1H),8.25(m,2H),8.57(m,1H)。
实施例7:4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,2,4-噁二唑-3-基)-2-甲基苯甲酸(7)的制备
与实施例1的制备方法相同,除了用4-氰基-2-甲基苯甲酸甲酯替代对氰基苯甲酸甲酯,制得标题化合物7。
MS:m/z=595.4[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.12(m,2H),1.26(m,2H),1.78(m,2H),1.76(m,4H),1.98(m,2H),2.34(m,1H),2.59(s,3H),3.48(m,1H),4.08(m,2H),4.27(s,2H),7.64(m,3H),7.95(m,3H)。
实施例8:4-(5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛-8-基)-1,3,4-噁二唑-2-基)苯甲酸(8)的合成
步骤1:2-(4-(甲氧基羰基)苯甲酰基)肼-1-甲酸叔丁酯(8B)的制备
将对苯二甲酸单甲酯(5.00g,27.8mmol)、二氯甲烷(80mL)、肼基甲酸叔丁酯(4.50g,34.4mmol)、DMAP(13.5g,111mmol)和EDCI(7.50g,38.9mmol)加入至反应瓶中,室温搅拌20小时。反应完成后,加入100mL水、100mL二氯甲烷萃取,有机相用水、饱和食盐水各洗涤一次,无水硫酸钠干燥,过滤,滤液减压浓缩,得到16.30g浅黄色固体状的标题产物,直接用于下一步,收率:100%。
步骤2:4-(肼基甲酰基)苯甲酸甲酯(8C)的制备
将2-(4-(甲氧基羰基)苯甲酰基)肼-1-甲酸叔丁酯(18.94g,64.4mmol)、乙酸乙酯(50mL)加入至反应瓶中,于0℃加入饱和盐酸乙酸乙酯溶液(40mL),然后于室温搅拌18小时。反应完成后,用饱和碳酸氢钠溶液调节pH至8~9,过滤,干燥,得到4.80g白色固体状标题产物,收率:38.4%。
步骤3:4-(1,3,4-噁二唑-2-基)苯甲酸甲酯(8D)的制备
将4-(肼基甲酰基)苯甲酸甲酯(3.00g,15.5mmol)、原甲酸三乙酯(11.40g,77.3mmol)加入至反应瓶中,于105℃搅拌16小时。反应完成后,将反应液减压浓缩,残余物通过硅胶柱层析色谱法纯化(洗脱剂:正庚烷∶乙酸乙酯=3∶1),得到1.00g白色固体状的标题产物,收率31.7%。
步骤4:(Z)-N-((E)-((1R,3r,5S)3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)亚甲基)4-(甲氧羰基)苯甲肼酸(8E)的制备
将4-(1,3,4-噁二唑-2-基)苯甲酸甲酯(0.50g,2.45mmol)、DMF(10mL)、4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2,6-二氯苯基)异噁唑(1C)(4.50g,34.4mmol)、TEA(2mL)加入至反应瓶中,于90℃搅拌18小时。反应完成后,向反应液中加入水(40mL)和二氯甲烷(40mL),有机相用水、饱和食盐水各洗涤一次,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物通过硅胶柱层析色谱法纯化(洗脱剂:二氯甲烷∶甲醇=20∶1),得到0.40g褐色固体状的标题产物,收率27.4%。
步骤5:4-(5-((1R,3r,5S)3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)8-氮杂双环[3.2.1]辛烷-8-基)1,3,4-噁二唑-2-基)苯甲酸甲酯(8F)的制备
将(Z)-N-((E)-((1R,3r,5S)3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)亚甲基)4-(甲氧羰基)苯甲肼酸(8E)(0.30g,0.5mmol)、二氯甲烷(10mL)、碘苯二乙酸(0.24g,0.756mmol)加入至反应瓶中,室温搅拌1小时。反应完成后,将反应液减压浓缩,残余物通过制备液相色谱法(洗脱剂:0%-100%乙腈:水)纯化,得到0.135g白色固体状标题产物,收率45.1%。
步骤6:4-(5-((1R,3r,5S)3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)1,3,4-噁二唑-2-基)苯甲酸(8)的制备
将4-(5-((1R,3r,5S)3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)1,3,4-噁二唑-2-基)苯甲酸甲酯(8F)(0.135g,0.23mmol)、甲醇(10mL)、水(5mL)、THF(15mL)、氢氧化锂(33mg,1.36mmol)加入至反应瓶中,于40℃搅拌24小时。反应完成后,将反应液用盐酸调节至pH=1~2,加入水(40mL)和乙酸乙酯(40mL),有机相用水、饱和食盐水各洗涤一次,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物通过制备液相色谱法(洗脱剂:0%-100%乙腈:水)纯化,得到56mg白色固体状标题产物,收率42.5%。
MS:m/z=581[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,4H),1.64(m,2H),1.76(m,4H),1.91(m,2H),2.38(m,1H),3.46(m,1H),4.04(m,2H),4.28(s,2H),7.62(m,3H),8.18(m,4H)。
实施例9:2-氯-4-(5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛-8-基)-1,3,4-噁二唑-2-基)苯甲酸(9)的制备
与实施例8的制备方法相同,除了用3-氯-4-(甲氧基羰基)苯甲酸替代对苯二甲酸单甲酯,制得标题化合物9。
MS:m/z=615.2[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,4H),1.64(m,2H),1.76(m,4H),1.91(m,2H),2.36(m,1H),3.48(m,1H),4.07(m,2H),4.27(s,2H),7.59(m,1H),7.67(m,2H),7.92(m,1H),8.04(m,1H),8.08(m,1H)。
实施例10:6-(5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)吡啶-2-甲酸(10)的制备
与实施例8的制备方法相同,除了用2,6-吡啶二羧酸单甲酯替代对苯二甲酸单甲酯,制得标题化合物10。
MS:m/z=582.2[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,4H),1.64(m,2H),1.75(m,4H),1.90(m,2H),2.35(m,1H),3.48(m,1H),4.09(m,2H),4.27(s,2H),7.72(m,3H),8.25(m,3H)。
实施例11:5-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)噻吩-2-甲酸(11)的制备
与实施例8的制备方法相同,除了用5-羧基噻吩-2-甲酸甲酯替代对苯二甲酸单甲酯,制得标题化合物11。
MS:m/z=587.1[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,4H),1.60(m,2H),1.74(m,4H),1.85(m,2H),2.35(m,1H),3.47(m,1H),4.02(m,2H),4.26(s,2H),7.61(m,3H),7.79(m,1H),7.90(m,1H)。
实施例12:4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-2-氟苯甲酸(12)的制备
与实施例8的制备方法相同,除了用3-氟-4-(甲氧基羰基)苯甲酸替代对苯二甲酸单甲酯,制得标题化合物12。
MS:m/z=599.4[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,4H),1.64(m,2H),1.75(m,4H),1.91(m,2H),2.32(m,1H),3.49(m,1H),4.06(m,2H),4.26(s,2H),7.63(m,3H),7.92(m,2H),8.06(m,1H)。
实施例13:4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-2-甲氧基苯甲酸(13)的制备
与实施例8的制备方法相同,除了用3-甲氧基-4-(甲氧基羰基)苯甲酸替代对苯二甲酸单甲酯,制得标题化合物13。
MS:m/z=611.2[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,4H),1.64(m,2H),1.76(m,4H),1.91(m,2H),2.32(m,1H),3.48(m,1H),3.92(m,3H),4.07(m,2H),4.26(s,2H),7.61(m,5H),7.77(m,1H)。
实施例14:4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-3-甲基苯甲酸(14)的制备
与实施例8的制备方法相同,除了用2-甲基-4-(甲氧基羰基)苯甲酸替代对苯二甲酸单甲酯,制得标题化合物14。
MS:m/z=595.4[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,4H),1.59(m,2H),1.76(m,4H),1.91(m,2H),2.37(m,1H),2.65(s,3H),3.48(m,1H),4.06(m,2H),4.28(s,2H),7.56(m,1H),7.66(m,2H),7.90(m,1H),7.96(m,1H),8.05(m,1H)。
实施例15:3-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)苯甲酸(15)的制备
与实施例8的制备方法相同,除了用3-(甲氧基羰基)苯甲酸替代对苯二甲酸单甲酯,制得标题化合物15。
MS:m/z=581.1[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,4H),1.60(m,2H),1.67(m,4H),1.88(m,2H),2.32(m,1H),3.48(m,1H),4.09(m,2H),4.26(s,2H),7.59(m,3H),7.77(m,1H),8.23(m,2H),8.51(m,1H)。
实施例16:4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-3-氟苯甲酸(16)的制备
与实施例8的制备方法相同,除了用2-氟-4-(甲氧基羰基)苯甲酸替代对苯二甲酸单甲酯,制得标题化合物16。
MS:m/z=599.4[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,4H),1.60(m,2H),1.62(m,4H),1.75(m,2H),2.31(m,1H),3.54(m,1H),4.04(m,2H),4.27(s,2H),7.64(m,4H),7.81(m,1H),7.92(m,1H)。
实施例17:4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-2-甲基苯甲酸(17)的制备
步骤1:2-(4-溴-3-甲基苯甲酰基)肼-1-羧酸叔丁酯(17B)的制备
将4-溴-3-甲基苯甲酸(5.98g,27.8mmol)、二氯甲烷(80mL)、肼基甲酸叔丁酯(4.50g,34.4mmol)、DMAP(13.5g,111mmol)和EDCI(7.50g,38.9mmol)加入至反应瓶中,室温搅拌20小时。反应完成后,加入100mL水、100mL二氯甲烷萃取,有机相用水、饱和食盐水各洗涤一次,无水硫酸钠干燥,过滤,滤液减压浓缩,得到8.90g浅黄色固体状的标题产物,直接用于下一步,收率:97.1%。
步骤2:4-溴-3-甲基苯甲酰肼(17C)的制备
将2-(4-溴-3-甲基苯甲酰基)肼-1-羧酸叔丁酯(8.90g,27.1mmol)、乙酸乙酯(50mL)加入至反应瓶中,于0℃加入饱和盐酸乙酸乙酯溶液(40mL),然后于室温搅拌18小时。反应完成后,用饱和碳酸氢钠溶液调节pH至8~9,过滤,干燥,得到5.60g白色固体状标题产物,收率:90.5%。
步骤3:2-(4-溴-3-甲基苯基)-1,3,4-噁二唑(17D)的制备
将4-溴-3-甲基苯甲酰肼(5.60g,24.5mmol)、原甲酸三乙酯(50mL)加入至反应瓶中,于105℃搅拌16小时。反应完成后,将反应液减压浓缩,残余物通过硅胶柱层析色谱法纯化(洗脱剂:正庚烷∶乙酸乙酯=3∶1),得到4.20g白色固体状的标题产物,收率71.8%。
步骤4:(Z)-4-溴-N-((E)-(((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)亚甲基)-3-甲基苯并肼基酸(17E)的制备
将2-(4-溴-3-甲基苯基)-1,3,4-噁二唑(0.50g,2.10mmol)、DMF(10mL)、4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2,6-二氯苯基)异噁唑(1C)(0.82g,2.10mmol)、DIPEA(5mL)加入至反应瓶中,于110℃搅拌18小时。反应完成后,向反应液中加入水(40mL)和二氯甲烷(40mL),有机相用水、饱和食盐水各洗涤一次,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物通过硅胶柱层析色谱法纯化(洗脱剂:二氯甲烷∶甲醇=20∶1),得到0.40g褐色固体状的标题产物,收率30.2%。
步骤5:2-(4-溴-3-甲基苯基)-5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8氮杂双环[3.2.1]辛-8-基)-1,3,4-噁二唑(17F)的制备
将(Z)-4-溴-N-((E)-(((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)亚甲基)-3-甲基苯并肼基酸(0.40g,0.63mmol)、二氯甲烷(10mL)、碘苯二乙酸(0.31g,0.95mmol)加入至反应瓶中,室温搅拌1小时。反应完成后,将反应液减压浓缩,残余物通过硅胶柱层析色谱法纯化(洗脱剂:石油醚∶乙酸乙酯=2∶1),得到0.35g黄色油状物标题产物,收率87.8%。
步骤6:4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-2-甲基苯甲酸甲酯(17G)的制备
将2-(4-溴-3-甲基苯基)-5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8氮杂双环[3.2.1]辛-8-基)-1,3,4-噁二唑(0.35g,0.56mmol)、Pd(dppf)Cl2(41mg,0.056mmol)、乙酸钠(92mg,1.12mmol)、甲醇(10mL)、DMF(3mL)加入至高压罐(TGYF,华欧)中,一氧化碳排空气三次,0.5mPa,80℃搅拌反应16小时。反应完成后,将反应液减压浓缩,残余物通过硅胶柱层析色谱法纯化(洗脱剂:石油醚∶乙酸乙酯=2∶1),得到0.20g黄色油状物标题产物,收率59.0%。
步骤7:4-(5-(((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-2-甲基苯甲酸(17)的制备将4-(5-(((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-2-甲基苯甲酸甲酯(0.20g,0.33mmol)、甲醇(10mL)、水(5mL)、THF(15mL)、氢氧化锂(33mg,1.36mmol)加入至反应瓶中,于40℃搅拌24小时。反应完成后,将反应液用盐酸调节至pH=1~2,加入水(40mL)和乙酸乙酯(40mL),有机相用水、饱和食盐水各洗涤一次,无水硫酸钠干燥,过滤,滤液减压浓缩,残余物通过制备液相色谱法(洗脱剂:0%-100%乙腈:水)纯化,得到76mg白色固体状标题产物,收率38.8%。
MS:m/z=595.3[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.14(m,4H),1.65(m,2H),1.79(m,4H),1.97(m,2H),2.36(m,1H),2.51(m,3H),3.50(m,1H),4.18(m,2H),4.28(s,2H),7.62(m,5H),7.92(m,1H)。
实施例18:5-(5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)吡啶甲酸(18)的制备
与实施例8的制备方法相同,除了用吡啶-2,5-二羧-2-甲基酯替代对苯二甲酸单甲酯,制得标题化合物18。
MS:m/z=582.5[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.14(m,4H),1.65(m,2H),1.79(m,4H),1.95(m,2H),2.35(m,1H),3.53(m,1H),4.19(m,2H),4.27(s,2H),7.59(m,3H),8.15(m,1H),8.38(m,1H),9.14(m,1H)。
实施例19:6-(5-((1R,3r,5S)-3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)烟酸(19)的制备
与实施例8的制备方法相同,除了用5-(甲氧羰基)-2-吡啶羧酸替代对苯二甲酸单甲酯,制得标题化合物19。
MS:m/z=582.5[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,4H),1.66(m,2H),1.79(m,4H),1.95(m,2H),2.35(m,1H),3.53(m,1H),4.20(m,2H),4.27(s,2H),7.62(m,3H),8.12(m,1H),8.39(m,1H),9.14(m,1H)。
实施例20:5-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)噻吩-3-羧酸(20)的制备
与实施例17的制备方法相同,除了用4-溴噻吩-2-甲酸替代4-溴-3-甲基苯甲酸,制得标题化合物20。
MS:m/z=587.7[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,4H),1.61(m,2H),1.76(m,4H),1.85(m,2H),2.33(m,1H),3.47(m,1H),4.12(m,2H),4.25(s,2H),7.58(m,3H),7.77(m,1H),8.39(m,1H)。
实施例21:4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2,6-二氯苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)噻吩-2-羧酸(21)的制备
与实施例17的制备方法相同,除了用5-溴-3-噻吩甲酸替代4-溴-3-甲基苯甲酸,制得标题化合物21。
MS:m/z=587.4[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.13(m,4H),1.68(m,2H),1.77(m,4H),1.85(m,2H),2.33(m,1H),3.47(m,1H),4.13(m,2H),4.26(s,2H),7.64(m,3H),7.94(m,1H),8.34(m,1H)。
实施例22:4-(5-((1R,3r,5S)-3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛-8-基)-1,3,4-噁二唑-2-基)苯甲酸(22)的合成
与实施例8的制备方法相同,除了用4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑(根据文献WO2012087519公开的方法制备)替代4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2,6-二氯苯基)异噁唑(1C),制得标题化合物22。
MS:m/z=597.7[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.13(m,4H),1.66(m,2H),1.80(m,4H),1.95(m,2H),2.33(m,1H),3.53(m,1H),4.17(m,2H),4.33(s,2H),7.82(m,4H),7.96(m,2H),8.08(m,2H)。
实施例23:2-氯-4-(5-((1R,3r,5S)-3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛-8-基)-1,3,4-噁二唑-2-基)苯甲酸(23)的制备
与实施例8的制备方法相同,除了用4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑(根据文献WO2012087519公开的方法制备)替代4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2,6-二氯苯基)异噁唑(1C)及3-氯-4-(甲氧基羰基)苯甲酸替代对苯二甲酸单甲酯,制得标题化合物23。
MS:m/z=631.5[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.13(m,4H),1.66(m,2H),1.79(m,4H),1.99(m,2H),2.33(m,1H),3.51(m,1H),4.20(m,2H),4.33(s,2H),7.55(m,2H),7.68(m,2H),7.89(m,2H),7.94(m,1H)。
实施例24:6-(5-((1R,3r,5S)-3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)吡啶-2-甲酸(24)的制备
与实施例8的制备方法相同,除了用4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑(根据文献WO2012087519公开的方法制备)替代4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2,6-二氯苯基)异噁唑(1C)及2,6-吡啶二羧酸单甲酯替代对苯二甲酸单甲酯,制得标题化合物24。
MS:m/z=598.5[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.13(m,4H),1.66(m,2H),1.79(m,4H),1.98(m,2H),2.33(m,1H),3.51(m,1H),4.20(m,2H),4.32(s,2H),7.62(m,4H),8.25(m,3H)。
实施例25:5-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)噻吩-2-甲酸(25)的制备
与实施例8的制备方法相同,除了用4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑(根据文献WO2012087519公开的方法制备)替代4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2,6-二氯苯基)异噁唑(1C)及5-羧基噻吩-2-甲酸甲酯替代对苯二甲酸单甲酯,制得标题化合物25。
MS:m/z=603.4[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,4H),1.65(m,2H),1.74(m,4H),1.79(m,2H),2.33(m,1H),3.53(m,1H),4.14(m,2H),4.32(s,2H),7.65(m,6H)。
实施例26:4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-2-氟苯甲酸(26)的制备
与实施例8的制备方法相同,除了用4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑(根据文献WO2012087519公开的方法制备)替代4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2,6-二氯苯基)异噁唑(1C)及3-氟-4-(甲氧基羰基)苯甲酸替代对苯二甲酸单甲酯,制得标题化合物26。
MS:m/z=615.3[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,4H),1.66(m,2H),1.79(m,4H),1.95(m,2H),2.32(m,1H),3.52(m,1H),4.15(m,2H),4.33(s,2H),7.62(m,2H),7.80(m,2H),7.89(m,2H),8.02(m,1H)。
实施例27:4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-3-甲基苯甲酸(27)的制备
与实施例8的制备方法相同,除了用4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑(根据文献WO2012087519公开的方法制备)替代4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2,6-二氯苯基)异噁唑(1C)及2-甲基-4-(甲氧基羰基)苯甲酸替代对苯二甲酸单甲酯,制得标题化合物27。
MS:m/z=611.4[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.16(m,4H),1.72(m,2H),1.77(m,4H),2.00(m,2H),2.43(m,1H),2.59(s,3H),3.54(m,1H),4.22(m,2H),4.30(s,2H),7.63(m,2H),7.71(m,2H),7.95(m,3H)。
实施例28:3-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)苯甲酸(28)的制备
与实施例8的制备方法相同,除了用4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑(根据文献WO2012087519公开的方法制备)替代4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2,6-二氯苯基)异噁唑(1C)及3-(甲氧基羰基)苯甲酸替代对苯二甲酸单甲酯,制得标题化合物28。
MS:m/z=597.2[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,4H),1.66(m,2H),1.79(m,4H),1.94(m,2H),2.33(m,1H),3.53(m,1H),4.17(m,2H),4.32(s,2H),7.65(m,5H),8.05(m,2H),8.35(m,1H)。
实施例29:4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-3-氟苯甲酸(29)的制备
与实施例8的制备方法相同,除了用4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑(根据文献WO2012087519公开的方法制备)替代4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2,6-二氯苯基)异噁唑(1C)及2-氟-4-(甲氧基羰基)苯甲酸替代对苯二甲酸单甲酯,制得标题化合物29。
MS:m/z=615.5[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,4H),1.66(m,2H),1.79(m,4H),1.90(m,2H),2.31(m,1H),3.52(m,1H),4.15(m,2H),4.32(s,2H),7.57(m,2H),7.67(m,2H),7.85(m,2H),8.02(m,1H)。
实施例30:4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)-2-甲基苯甲酸(30)的制备
与实施例17的制备方法相同,除了用4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑(根据文献WO2012087519公开的方法制备)替代4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2,6-二氯苯基)异噁唑(1C),制得标题化合物30。
MS:m/z=611.4[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.11(m,4H),1.67(m,2H),1.80(m,4H),2.08(m,2H),2.33(m,1H),2.54(m,1H),3.54(m,1H),4.19(m,2H),4.34(s,2H),7.67(m,6H),7.93(m,1H)。
实施例31:5-(5-((1R,3r,5S)-3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)吡啶甲酸(31)的制备
与实施例8的制备方法相同,除了用4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑(根据文献WO2012087519公开的方法制备)替代4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2,6-二氯苯基)异噁唑(1C)及吡啶-2,5-二羧酸-2-甲基酯替代对苯二甲酸单甲酯,制得标题化合物31。
MS:m/z=598.5[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.10(m,4H),1.68(m,2H),1.80(m,4H),1.98(m,2H),2.35(m,1H),3.53(m,1H),4.20(m,2H),4.34(s,2H),7.59(m,4H),8.15(m,1H),8.36(m,1H),9.14(m,1H)。
实施例32:6-(5-((1R,3r,5S)-3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)烟酸(32)的制备
与实施例8的制备方法相同,除了用4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑(根据文献WO2012087519公开的方法制备)替代4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2,6-二氯苯基)异噁唑(1C)及5-(甲氧羰基)-2-吡啶羧酸替代对苯二甲酸单甲酯,制得标题化合物32。
MS:m/z=598.5[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.13(m,4H),1.69(m,2H),1.81(m,4H),1.95(m,2H),2.35(m,1H),3.53(m,1H),4.18(m,2H),4.28(s,2H),7.63(m,4H),8.12(m,1H),8.39(m,1H),9.14(m,1H)。
实施例33:5-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)噻吩-3-羧酸(33)的制备
与实施例17的制备方法相同,除了用4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑(根据文献WO2012087519公开的方法制备)替代4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2,6-二氯苯基)异噁唑(1C)及4-溴噻吩-2-甲酸替代4-溴-3-甲基苯甲酸,制得标题化合物33。
MS:m/z=603.3[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.13(m,4H),1.66(m,2H),1.79(m,4H),1.85(m,2H),2.35(m,1H),3.34(m,1H),4.15(m,2H),4.33(s,2H),7.57(m,4H),7.79(m,1H),8.38(m,1H)。
实施例34:4-(5-((1R,3r,5S)-(3-((5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑-4-基)甲氧基)-8-氮杂双环[3.2.1]辛烷-8-基)-1,3,4-噁二唑-2-基)噻吩-2-羧酸(34)的制备
与实施例17的制备方法相同,除了用4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2-(三氟甲氧基)苯基)异噁唑(根据文献WO2012087519公开的方法制备)替代4-((((1R,3r,5S)-8-氮杂双环[3.2.1]辛-3-基)氧基)甲基)-5-环丙基-3-(2,6-二氯苯基)异噁唑(1C)及5-溴-3-噻吩甲酸替代4-溴-3-甲基苯甲酸,制得标题化合物34。
MS:m/z=603.4[M+H]+。
1H NMR(300MHz,DMSO):δppm 1.17(m,4H),1.72(m,2H),1.85(m,4H),1.93(m,2H),2.56(m,1H),3.53(m,1H),4.18(m,2H),4.38(s,2H),7.61(m,2H),7.70(m,2H),8.01(m,1H),8.41(m,1H)。
本发明化合物的生物学评价
测试例1:本发明化合物对FXR激动活性的评价
采用荧光素酶报告基因实验(luciferase assay)评价本发明化合物对FXR激动活性。
实验过程包括:传luc2P-GAL4-HEK293稳转细胞系(由HEK293细胞转染pGL4.35质粒,经Hygromycin B筛选建立。该细胞含有9×GAL4 UAS和萤火虫荧光素酶报告基因。配体激活的LBD-GAL4 DBD融合蛋白可以入核与9×GAL4 UAS结合并激活下游荧光素酶报告基因的转录)至96孔板,每孔1×104细胞。使用X-tremeGENE HP转染试剂转染pBIND-FXR(由FXR-LBD插入pFN26A-BIND hRluc-neo载体构建而成。质粒大小7.5kb,Amp抗性,含有FXR-LBD,可表达FXR-LBD和GAL4DBD融合蛋白),质粒与转染试剂比例为1μg:2μl,具体用量为每孔100ng质粒,0.2μl X-tremeGENE HP转染试剂;加入待测化合物(各化合物加药最高浓度为30μM,3倍稀释,共计10个浓度),诱导荧光素酶表达。24小时后,将含有待测细胞的96孔板从孵箱中取出,置于室温,每孔加入与孔内培养基体积相等的 LuciferaseReagent(80μl/孔),混匀,室温孵育20min,让细胞充分裂解,然后将孔板中的所有液体转移至96孔酶标板中,用多功能读板仪(厂家:Bio Tek(USA);型号:Synergy4)测量萤火虫萤光素值;向每孔中加入与初始培养基体积相等的 Stop& Reagent(80μl/孔),混匀,室温孵育10min,然后测量海肾萤光素值。海肾萤光的测量顺序应该与萤火虫萤光相同。使用GraphPad Prism 5软件,采用非线性回归方法进行曲线拟合及EC50计算,拟合方程为:Y=Bottom+(Top-Bottom)/(1+10^((LogEC50-X)*HillSlope))。其中,EC50是半有效浓度,Top为最大效应,Bottom为空白效应,HillSlope为斜率。化合物的活性如表1所示。
在表1中,A是指化合物激动FXR活性的EC50<25nM;B是指EC50=25nM至50nM;C是指EC50=50nM至100nM;D是指EC50=100nM至500nM;E是指EC50>500nM。
表1.本发明化合物的FXR激动活性
结论:如上表1所述,本发明化合物显示出体外FXR的激动活性。
测试例2:本发明化合物对1-萘异硫氰酸酯(ANIT)诱导的大鼠胆汁酸淤积模型的疗效
动物:SD大鼠,雄性,7-8周龄,体重220-240g,购于北京市维通利华实验动物技术有限公司,SPF级,动物生产许可证号:SCXK(京)2016-0011,发证单位:北京市科学技术委员会。
样品配制:将本发明化合物加入至DMSO中,超声至完全溶解。加入0.5%CMC-Na定容(DMSO:0.5%CMC-Na=1∶99)后再超声至溶解均一,备用。
动物适应3-5天后,动物按体重分为20组:正常组、模型组、实施例8(3mg/kg/d、10mg/kg/d)组、实施例11(3mg/kg/d、10mg/kg/d)组、实施例12(3mg/kg/d、10mg/kg/d)组、实施例14(3mg/kg/d、10mg/kg/d)组、实施例20(3mg/kg/d、10mg/kg/d)组、实施例22(3mg/kg/d、10mg/kg/d)组、实施例26(3mg/kg/d、10mg/kg/d)组、实施例28(3mg/kg/d、10mg/kg/d)组、实施例29(3mg/kg/d、10mg/kg/d)组,每组10只,开始灌胃给药,给药体积为10mL/kg,每天给药1次,共给药4天。给药第2天,除正常组外每只动物灌胃给予ANIT(1-萘异硫氰酸酯,麦克林,纯度98%,货号:N814658,CAS号:551-06-4,规格:5g/瓶存储条件:2-8度,批号:C10116101。)一次,在给药后4小时给予,剂量为50mg/kg,给药体积5mL/kg,第4天早上禁食。用小动物麻醉机,采用异氟烷吸入麻醉后,用毛细玻璃管,眼球后静脉丛取血放置1小时左右,每只约1ml左右,3500转/分,离心10分钟,取血清,采用AU480全自动生化分析系统(BECKMAN COULTER)测ALT、AST、GGT和TBA指标并测血药浓度。取肝脏,称重,剪碎,加生理盐水(肝脏重量∶生理盐水=1∶2),匀浆后冻存测肝药浓度,采用超高效液相色谱仪:Shimadzu,LC 30AD;三重四级杆质谱仪:AB,TQ5500检测。
本发明化合物对ANIT诱导胆汁酸淤积大鼠的疗效如下表2所示。本发明化合物在ANIT诱导胆汁酸淤积大鼠给药4天的血药浓度和肝药浓度如下表3、表4和表5所示。
表2.本发明化合物对ANIT诱导胆汁酸淤积大鼠的疗效
注明:*为与模型组比较P<0.05,**为与模型组比较P<0.01。
表3.本发明化合物给药4天血药浓度结果
表4.本发明化合物给药4天肝药浓度结果
表5.本发明化合物给药4天肝药浓度/血药浓度结果
结论:本发明实施例8、11、12、14、20、22、26、28、29显著降低ANIT大鼠血清中的ALT、AST、GGT和TBA水平,说明本发明化合物可显著改善ANIT大鼠的胆汁淤积。而且,这些化合物具有较高的肝脏靶向性。
测试例3:本发明化合物对hERG通道的作用测试
试验试剂:
试验仪器:
名称 | 供应商 | 型号 |
放大器 | HEKA(Germany) | EPC10 |
微操纵器 | Sutter Instruments(USA) | MP285 |
电极拉制仪 | Sutter Instruments(USA) | P97 |
显微镜 | Olympus(Japan) | IX71 |
毛细玻璃管 | Sutter Instruments(USA) | BF150-86-10 |
数据采集和分析软件 | HEKA(Germany) | Patchmaster&IGOR |
细胞内外液:
细胞外液:140mM NaCl,3.5mM KCl,1mM MgCl2,2mM CaCl2,10mM葡萄糖,10mMHEPES,1.25mM NaH2PO4,NaOH调节pH=7.4。
细胞内液:20mM KCl,115mM K-天冬氨酸,1mM MgCl2,5mM EGTA,10mM HEPES,2mMNa2-ATP,KOH调节pH=7.2。
待测样品配制:
用10mL的细胞外液将本发明实施例8化合物储液(30.26mM的DMSO溶液)依次稀释,配成0.3μM、1μM、3μM、0μM以及30μM液体。目测待测样品的溶解性,待测样品全部溶解没有肉眼可见的沉淀。
西沙必利(阳性对照)配制:
将10mg西沙必利用2066.29μL二甲基亚砜(DMSO)配制成10mM的储液。用二甲基亚砜(DMSO)将西沙必利储液依次稀释为1μM、10μM、100μM以及1mM,共4个浓度。在检测之前,每个浓度各取10μL加入到10mL细胞外液中,确保DMSO浓度为0.1%。西沙必利最终的工作浓度为1nM、10nM、100nM以及1μM。目测西沙必利的溶解性,西沙必利全部溶解没有肉眼可见的沉淀。
细胞培养:
hERG钾通道稳定表达的HEK293细胞系(供应商Creacell,货号A-0302)在含有10%胎牛血清及0.8mg/mL G418的DMEM培养基中培养,培养温度为37℃,二氧化碳浓度为5%。
细胞传代:除去旧培养基并用PBS洗一次,然后加入1mL TrypLETM表达溶液,37℃孵育0.5分钟。当细胞从皿底脱离,加入5mL 37℃预热的完全培养基(含10%胎牛血清及0.8mg/mL G418的DMEM培养基)。将细胞悬液用吸管轻轻吹打使聚集的细胞分离。将细胞悬液转移至无菌的离心管中,1000rpm离心5分钟收集细胞。扩增或维持培养,将细胞接种于6厘米细胞培养皿,每个细胞培养皿接种细胞量为2.5×105个细胞(最终体积:5mL)。为维持细胞的电生理活性,细胞密度必须不能超过80%。膜片钳检测,实验之前细胞用TrypLETM表达溶液分离,将3×103细胞铺到盖玻片上,在24孔板中培养(最终体积:500μL),18个小时后,进行实验检测。
电生理记录实验方法:
全细胞膜片钳记录全细胞hERG钾电流的电压刺激方案如下:当形成全细胞封接后膜片钳设置于-80mV。钳制电压由-80mV除极至+30mV维持2.5秒,然后迅速保持在-50mV维持4秒,可以激发出hERG通道的尾电流。实验以-50mV为漏电流检测。每隔10秒重复采集数据,观察药物对hERG尾电流的作用。实验数据由EPC-10放大器(HEKA)进行采集并储存于PatchMaster(HEKA)软件中。
用微电极拉制仪(P97,Sutter Instruments)将毛细玻璃管(BF150-86-10,SutterInstruments)拉制成记录电极。在倒置显微镜(IX71,Olympus)下操纵微电极操纵仪(MP285,Sutter Instruments)将记录电极接触到细胞上,给予负压抽吸,形成GΩ封接。形成GΩ封接后进行快速电容补偿,然后继续给予负压,吸破细胞膜,形成全细胞记录模式。然后进行慢速电容的补偿并记录膜电容及串联电阻。不给予漏电补偿。
当全细胞记录的hERG电流稳定后开始给药,每个药物浓度作用至5分钟(或者电流至稳定)后检测下一个浓度,每一个测试化合物检测多个浓度。将铺有细胞的盖玻片置于倒置显微中的记录浴槽中,测试化合物以及不含化合物的外液利用重力灌流的方法从低浓度到高浓度依次流经记录小室从而作用于细胞,在记录中利用真空泵进行液体交换。每一个细胞在不含化合物的外液中检测到的电流作为自己的对照组。独立重复检测3个细胞。所有电生理实验在室温下进行。
数据质量标准:
以下标准用来判断数据是否可以接受:
(1)串联电阻≤20MΩ
(2)封接电阻≥1GΩ
(3)起始尾电流峰值≥400pA
(4)起始尾电流峰值大于激活电流峰值
(5)尾电流没有明显的自发性衰减(5分钟内自发性衰减小于5%)
(6)在膜电位为-80mV下无明显的漏电流(漏电流≤100pA)
本发明实施例8化合物对hERG通道抑制作用以及半抑制浓度(IC50)结果如下表6所示。
表6.本发明实施例8化合物对hERG通道抑制作用以及半抑制浓度(IC50)
实验结果表明:本发明实施例8化合物对hERG通道无抑制作用。
Claims (8)
2.一种药物组合物,其含有根据权利要求1所述的化合物或其可药用盐,以及药学上可接受的载体。
3.根据权利要求1所述的化合物或其可药用盐或者根据权利要求2所述的药物组合物在制备FXR激动剂中的用途。
4.根据权利要求1所述的化合物或其可药用盐或者根据权利要求2所述的药物组合物在制备治疗与FXR活性相关的疾病的药物中的用途。
5.根据权利要求4所述的用途,其中所述与FXR活性相关的疾病选自:慢性肝内胆汁郁积病症或肝外胆汁郁积病症,或慢性胆汁郁积病症或急性肝内胆汁郁积病症导致的肝纤维化;和/或肝脏梗阻性或慢性炎症;和/或肝硬化;和/或肝皮脂腺病和相关的综合征,与酒精诱导的肝硬变或与病毒性肝炎相关的胆汁郁积或纤维变性作用;和/或肝脏切除后的肝脏衰竭或肝脏缺血;和/或急性肝脏衰竭;和/或炎性肠病;和/或脂质和脂质蛋白紊乱;和/或糖尿病性肾病、糖尿病性神经病、糖尿病视网膜病;和/或甘油三酯蓄积,及甘油三酯蓄积导致的慢性脂肪和纤维变性引起的疾病和病症;和/或肥胖或代谢综合征;和/或作为慢性梗阻性动脉粥样硬化终末点而产生的急性心肌梗塞、急性中风、或血栓形成;非恶性过度增殖性疾病和恶性过度增殖性疾病。
6.根据权利要求5所述的用途,其中所述甘油三酯蓄积导致的慢性脂肪和纤维变性引起的疾病和病症为非酒精性脂肪肝或非酒精性脂肪肝炎。
7.根据权利要求5所述的用途,其中所述代谢综合征为血脂障碍、糖尿病、体重指数异常高的合并病症。
8.根据权利要求5所述的用途,其中所述非恶性过度增殖性疾病和恶性过度增殖性疾病为肝细胞癌、结肠腺瘤和息肉病、结肠腺癌、乳腺癌、胰腺癌、巴特氏食管癌和其他形式的胃肠道和肝脏肿瘤性疾病。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910096771 | 2019-01-31 | ||
CN2019100967718 | 2019-01-31 | ||
PCT/CN2020/072763 WO2020156241A1 (zh) | 2019-01-31 | 2020-01-17 | 芳环或芳杂环类化合物及其制备方法和医药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112955448A CN112955448A (zh) | 2021-06-11 |
CN112955448B true CN112955448B (zh) | 2023-02-03 |
Family
ID=71841921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080006066.5A Active CN112955448B (zh) | 2019-01-31 | 2020-01-17 | 芳环或芳杂环类化合物及其制备方法和医药用途 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220127258A1 (zh) |
EP (1) | EP3919489A4 (zh) |
JP (1) | JP2022518603A (zh) |
KR (1) | KR20210123337A (zh) |
CN (1) | CN112955448B (zh) |
AU (1) | AU2020214889A1 (zh) |
CA (1) | CA3128416A1 (zh) |
TW (1) | TW202115052A (zh) |
WO (1) | WO2020156241A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023510274A (ja) | 2020-01-15 | 2023-03-13 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | D型肝炎ウイルスによる感染を処置するためのfxrアゴニストの使用 |
CN114195776B (zh) * | 2020-09-18 | 2023-06-20 | 凯思凯迪(上海)医药科技有限公司 | 新型fxr小分子激动剂制备及其用途 |
CN114195777B (zh) * | 2020-09-18 | 2023-06-20 | 凯思凯迪(上海)医药科技有限公司 | 新型fxr小分子激动剂制备及其用途 |
CN114315830A (zh) * | 2020-09-30 | 2022-04-12 | 中国科学院上海药物研究所 | Fxr小分子激动剂及其制备方法和用途 |
JP2024502673A (ja) | 2021-01-14 | 2024-01-22 | ウエヌイグレックオ・ファーマ | Hbv感染の処置のためのfxrアゴニストとifnの相乗効果 |
TW202308629A (zh) | 2021-04-28 | 2023-03-01 | 法商Enyo製藥公司 | 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效 |
EP4245365A1 (en) * | 2022-03-16 | 2023-09-20 | Cascade Pharmaceuticals, Inc. | A fxr small molecule agonist, the preparation and use thereof |
WO2023223257A1 (en) * | 2022-05-19 | 2023-11-23 | X-Chem Inc. | Amino heteroaromatic compounds |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018026890A1 (en) * | 2016-08-03 | 2018-02-08 | Cymabay Therapeutics | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
WO2018067704A1 (en) * | 2016-10-04 | 2018-04-12 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
JP2014500319A (ja) * | 2010-12-20 | 2014-01-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ファルネソイドx受容体を調節するための組成物および方法 |
WO2012168315A1 (en) * | 2011-06-09 | 2012-12-13 | Boehringer Ingelheim International Gmbh | Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders |
MX2015015130A (es) * | 2013-05-01 | 2016-02-18 | Hoffmann La Roche | Compuestos de biheteroarilo y usos de los mismos. |
KR20170095965A (ko) * | 2014-12-18 | 2017-08-23 | 노파르티스 아게 | 간 및 위장 질환의 치료에 사용하기 위한 fxr 효능제로서의 아자비시클로옥탄 유도체 |
CN106946867B (zh) * | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
US10526345B2 (en) * | 2016-04-08 | 2020-01-07 | Mankind Pharma Ltd. | Compounds as GPR119 agonists |
JP7243959B2 (ja) * | 2017-12-22 | 2023-03-22 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | イソオキサゾール誘導体、その製造方法、及びその使用 |
CN111868056B (zh) * | 2018-07-11 | 2023-02-03 | 中国医药研究开发中心有限公司 | 1,2,4-噁二唑类化合物及其制备方法和医药用途 |
-
2020
- 2020-01-17 CA CA3128416A patent/CA3128416A1/en active Pending
- 2020-01-17 JP JP2021544611A patent/JP2022518603A/ja active Pending
- 2020-01-17 KR KR1020217027636A patent/KR20210123337A/ko not_active Application Discontinuation
- 2020-01-17 WO PCT/CN2020/072763 patent/WO2020156241A1/zh unknown
- 2020-01-17 AU AU2020214889A patent/AU2020214889A1/en active Pending
- 2020-01-17 CN CN202080006066.5A patent/CN112955448B/zh active Active
- 2020-01-17 US US17/310,432 patent/US20220127258A1/en active Pending
- 2020-01-17 EP EP20749262.0A patent/EP3919489A4/en not_active Withdrawn
- 2020-01-30 TW TW109102816A patent/TW202115052A/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018026890A1 (en) * | 2016-08-03 | 2018-02-08 | Cymabay Therapeutics | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
WO2018067704A1 (en) * | 2016-10-04 | 2018-04-12 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
Non-Patent Citations (1)
Title |
---|
A Metal-Free Route to 2-Aminooxazoles by Taking Advantage of the Unique Ring Opening of Benzoxazoles and Oxadiazoles with Secondary Amines;Jomy Joseph et al.,;《Chem. Eur. J.》;20110607;第17卷;第8297页表4 * |
Also Published As
Publication number | Publication date |
---|---|
KR20210123337A (ko) | 2021-10-13 |
EP3919489A1 (en) | 2021-12-08 |
JP2022518603A (ja) | 2022-03-15 |
EP3919489A4 (en) | 2022-10-12 |
CA3128416A1 (en) | 2020-08-06 |
AU2020214889A1 (en) | 2021-09-02 |
US20220127258A1 (en) | 2022-04-28 |
CN112955448A (zh) | 2021-06-11 |
WO2020156241A1 (zh) | 2020-08-06 |
TW202115052A (zh) | 2021-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112955448B (zh) | 芳环或芳杂环类化合物及其制备方法和医药用途 | |
CN112876467B (zh) | Fxr受体激动剂 | |
CN111868056B (zh) | 1,2,4-噁二唑类化合物及其制备方法和医药用途 | |
CN110637015B (zh) | 法尼醇x受体激动剂及其用途 | |
JP7243959B2 (ja) | イソオキサゾール誘導体、その製造方法、及びその使用 | |
WO2018133730A1 (zh) | 一种杂环化合物及其制备方法和用途 | |
WO2004106276A1 (ja) | 縮合環化合物 | |
CN111107848A (zh) | 一种含有酰胺类衍生物的药物组合物及其制备方法和应用 | |
TWI801492B (zh) | 含氮三環化合物及其在藥物中的應用 | |
WO2020114307A1 (zh) | 异噁唑衍生物及其制备方法和用途 | |
US10105373B2 (en) | Fused triterpene compounds and uses thereof | |
JP7263659B2 (ja) | カルボン酸基を含む窒素含有ベンゾ複素環化合物、その調製方法及び使用 | |
CN107849008B (zh) | 一种八氢环戊烷并[c]吡咯衍生物及其制备方法和在医药上的用途 | |
CN112209896B (zh) | 噻唑烷二酮衍生物以及包含其的药物组合物 | |
CN110563720B (zh) | 磺酰胺类化合物及其制备方法和医药用途 | |
CN116903571A (zh) | 一种异黄酮化合物或其药物学上可接受的酯或药物学上的盐、制备方法及其在制备治疗体内疼痛药物、降糖药物中的用途 | |
WO2023205507A1 (en) | Androgen receptor modulators and methods for their use | |
CN108239029A (zh) | 一类四氢异喹啉化合物及其盐的制备和医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |